Stockwinners Market Radar for December 09, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

17:44 EST Rigetti Computing director Clifton sells 125,000 common shares - In a regulatory filing, Rigetti Computing director Michael Clifton disclosed the sale of 125,000 common shares of the company on December 9 at a price of $5.03 per share.

17:25 EST Invesco announces November-end AUT $1.86T - Invesco "reported preliminary month-end assets under management of $1,856.5 billion, an increase of 4.8% versus previous month-end. The firm delivered net long-term inflows of $11.0 billion in the month. Non-management fee earning net inflows were $9.2 billion and money market net inflows were $14.9 billion. AUM was positively impacted by favorable market returns which increased AUM by $52 billion. FX decreased AUM by $3.0 billion. Preliminary average total AUM for the quarter through November 30 were $1,805.4 billion, and preliminary average active AUM for the quarter through November 30 were $1,021.0 billion."

17:16 EST Momentus announces a 1-for-14 reverse stock split - Momentus announced it has effectuated a 1-for-14 reverse stock split of its Class A common stock that will become effective on December 12 at 5:00 p.m. Eastern Time. The company's common stock will continue to trade on the Nasdaq Global Select Market under the symbol "MNTS" and will begin trading on a split-adjusted basis at the opening of the market on December 13. The new CUSIP number for the common stock following the Reverse Stock Split will be 60879E309.

17:10 EST Northrop Grumman awarded $801.05M Air Force contract - Northrop Grumman was awarded a ceiling $801.05M indefinite-delivery/indefinite-quantity contract for combat air forces distributed mission operations services. This contract provides for virtual, distributed training to Air Force trainers worldwide including daily team training to large scale exercises. Work will be performed in Orlando, Florida, and is expected to be completed by Dec. 11, 2034. This contract was a competitive acquisition, and three offers were received. FY25 operation and maintenance funds in the amount of $5,526 are being obligated at the time of award. The Air Force Lifecycle Management Center is the contracting activity.

16:47 EST Century Aluminum VP Gudlaugsson sells $477K in company shares - Century Aluminum VP, Gunnar Gudlaugsson, disclosed the sale of 20,000 shares of company stock at $23.85 per share on Decemebr 5, for a transaction amount of $477,000.

16:43 EST TJX CEO Herrman sells over $950K in company shares - The CEO of TJX Ernie Herrman disclosed the sale of 7,533 shares of company stock at $126.18 per share on December 5, for a total transaction amount of $950,551.

16:34 EST Toll Brothers sees Q1 deliveries 1,900-2,100 units - Sees Q1 average delivered price per home $925,000-$945,000. Sees Q1 tax rate 22%

16:33 EST Roche commences tender offer for outstanding Poseida shares at $9 per share - Roche (RHHBY) announced that it has commenced a tender offer for all of the outstanding shares of common stock of Poseida Therapeutics, Inc. (PSTX) at a price of $9.00 per share in cash, plus a non-tradeable contingent value right to receive certain contingent payments of up to an aggregate of $4.00 per share in cash. The tender offer is being made pursuant to the previously announced merger agreement dated as of November 25, 2024 among Roche Holdings, Inc., an indirect wholly owned subsidiary of Roche Holding Ltd, Blue Giant Acquisition Corp., a wholly owned subsidiary of Roche Holdings, Inc., and Poseida. The tender offer period will expire at one minute following 11:59 p.m., New York City time on 7 January, 2025, unless the offer is extended. Roche has filed a tender offer statement on Schedule TO with the United States Securities and Exchange Commission. Blue Giant Acquisition Corp. is the acquirer in the tender offer. The Offer to Purchase contained within the Schedule TO sets out the terms and conditions of the tender offer.

16:31 EST Crane names Alex Alcala as new COO - Crane Company promoted Alejandro Alcala to Chief Operating Officer, effective immediately. In this role, Alex will provide both strategic and operational oversight of all Crane business segments, as well as the Crane Business System organization. Alex joined Crane in 2013 as President of Crane Pumps & Systems and was then promoted to President of Crane ChemPharma & Energy in 2014.

16:30 EST Phreesia jumps 6% to $22.83 after Q3 results, updated guidance

16:28 EST Smartsheet shareholders approve acquisition by Blackstone and Vista Equity - Smartsheet "announced that Smartsheet shareholders overwhelmingly approved the Merger Proposal for the Company's proposed acquisition by funds managed by Blackstone and Vista Equity Partners. This approval satisfies the shareholder vote condition for the consummation of the acquisition, originally announced in September 2024. In addition, shareholders also voted in favor of the executive compensation plan related to the acquisition, further validating their support for the Company's leadership and strategic direction."

16:25 EST Cohen & Steers reports preliminary AUM of $91.4B as of November 30 - Cohen & Steers reported preliminary assets under management of $91.4B as of November 30, an increase of $1.7B from assets under management of $89.7B at October 31. The increase was due to market appreciation of $1.9B, partially offset by distributions of $151M and net outflows of $98M.

16:22 EST Brookdale Senior Living announces November occupancy of 79.5% - November 2024 Observations: November weighted average occupancy increased 110 basis points year-over-year to 79.5% in 2024. Demonstrating an improvement to recent years, November weighted average occupancy increased 10 basis points sequentially from October. Month end occupancy exceeded 80% for the fourth consecutive month. Fourth quarter-to-date move-ins and move-outs improved to the prior year comparable period supporting a 100 basis point weighted average occupancy increase over 2023 fourth quarter-to-date.

16:21 EST Nanobiotix completes dose escalation-expansion parts of NBTXR3 in PC - Nanobiotix announced the completion of the dose escalation and dose expansion parts of a Phase 1 study evaluating radiotherapy or T R -activated NBTXR3 or JNJ-1900 for patients with locally advanced pancreatic cancer or LAPC, or borderline resectable pancreatic cancer or BRPC . The Phase 1 study is being conducted by The University of Texas MD Anderson Cancer Center or MD Anderson. Patients with LAPC or BRPC often receive initial treatment with cytotoxic chemotherapy followed by RT +/- concurrent or maintenance chemotherapy...Following these encouraging results from the study, MD Anderson submitted and received US FDA clearance for a new, additional study cohort evaluating the combination of NBTXR3 and standard-of-care concurrent chemoradiation. The new cohort has launched, and recruitment is ongoing. "The results we have observed in this Phase 1 study give us confidence that NBTXR3 could have a significant impact for these patients," said Louis Kayitalire, MD, Chief Medical Officer at Nanobiotix. "We look forward to the data from the new cohort and believe the combination of NBTXR3 and concurrent chemoradiation could produce even more favorable outcomes for patients with locally advanced or borderline resectable pancreatic cancer." Nanobiotix expects full results from the completed dose escalation and dose expansion parts of the study to be presented by MD Anderson at a medical congress in 1H 2025.

16:21 EST Autodesk director Norrington sells 1,778 common shares - In a regulatory filing, Autodesk director Lorrie Norrington disclosed the sale of 1,778 common shares of the company on December 6 at a price of $305.92 per share.

16:19 EST Krystal Biotech announces no major objections from CHMP on B-VEC approval - Krystal Biotech announced that the European Medicines Agency's, or EMA's, Committee for Medicinal Products for Human Use, or CHMP, cancelled the Oral Explanation regarding the company's marketing authorization application for beremagene geperpavec-svdt, or B-VEC, for the treatment of dystrophic epidermolysis bullosa, or DEB, that was scheduled for December 6 and asked the company to submit written responses to the remaining outstanding issues. There are no major objections outstanding from the EMA with respect to the full approval of B-VEC. The company now anticipates a CHMP opinion in Q1 2025 while the launch timelines remain unchanged with a commercial launch in Germany still planned for Q2 2025.

16:18 EST Essential Properties Realty Trust ups quarterly dividend 2% to 29.5c per share - Essential Properties Realty Trust announced that its Board of Directors declared a quarterly cash dividend of 29.5c per share of common stock for the fourth quarter of 2024. On an annualized basis the fourth quarter 2024 dividend of 29.5c equals $1.18 per share, an increase of 2c per share compared to the previous annualized dividend. The dividend is payable on January 14, 2025, to stockholders of record as of the close of business on December 31, 2024.

16:17 EST Celanese names Scott Richardson CEO - Celanese Corporation announced that Scott Richardson, currently Celanese's Chief Operating Officer, has been appointed Chief Executive Officer and will join the Company's Board of Directors, effective January 1, 2025. Richardson will succeed Lori Ryerkerk, who is stepping down as Chairman, CEO and director of Celanese at the end of the year. Celanese has elected Edward Galante, an independent director on Celanese's Board since 2013, as Chair of the Board, effective upon Ryerkerk's departure. Over his two decades of service at Celanese, Scott Richardson has served in a number of key management roles, including Chief Operating Officer, Chief Financial Officer and leadership positions overseeing Celanese's leading global Engineered Materials and Acetyl Chain businesses. Richardson was intimately involved in creating and implementing the EM and AC operating models that work together as a strategic pair to create value. "It is an incredible honor to be named CEO-elect of Celanese, and I am grateful to our Board of Directors for entrusting me with this responsibility," said Richardson. "Celanese is known for tenacious execution, even during difficult times, and I am confident we have all the critical components to create value for our shareholders, customers, employees and partners. I am fully committed to driving the changes needed in light of today's challenges, including our relentless efforts to improve our cost structure and drive cash generation. By executing our action plan and controlling what we can control, we are working to position Celanese to capitalize on its significant upside potential, resilient free cash flow and long-term value creation."

16:17 EST Cumberland announces FDA approves sNDA for Acetadote product - Cumberland Pharmaceuticals announced the FDA has approved a supplemental New Drug Application for its Acetadote product. Acetadote is an intravenous formulation of N-acetylcysteine indicated to prevent or lessen liver injury after ingestion of potentially toxic quantities of acetaminophen.

16:15 EST Vail Resorts to invest $198M-$203M in core capital in FY25 - Vail Resorts is committed to enhancing the guest experience and supporting the Company's growth strategies through significant capital investments. For calendar year 2025, the Company plans to invest approximately $198 million to $203 million in core capital, before $45 million of growth capital investments at its European resorts, including $41 million at Andermatt-Sedrun and $4 million at Crans-Montana, and $6 million of real estate related capital projects to complete multi-year transformational investments at the key base area portals of Breckenridge Peak 8 and Keystone River Run, and planning investments to support the development of the West Lionshead area into a fourth base village at Vail Mountain. Including European growth capital investments, and real estate related capital, the Company plans to invest approximately $249 million to $254 million in calendar year 2025. Projects in the calendar year 2025 capital plan described herein remain subject to approvals.

16:13 EST Yext raises FY25 adjusted EBITDA view to $67.0M-$67.5M from $66.0M-$67.0M

16:11 EST Fate Therapeutics presents new data from FT819 study - Fate Therapeutics presented new clinical and translational data from the company's FT819 Phase 1 Autoimmunity study for moderate-to-severe systemic lupus erythematosus, or SLE, at the American Society of Hematology, or ASH, annual meeting being held in San Diego. The first three study patients, each of whom presented with active lupus nephritis, or LN, despite having been treated with multiple standard-of-care therapies, received fludarabine-free conditioning followed by a single dose of FT819 at 360 million cells. There were no dose-limiting toxicities, no events of any grade of cytokine release syndrome, immune effector-cell associated neurotoxicity syndrome, or graft-versus-host disease and rapid, deep, and sustained elimination of CD19+ B cells in the periphery was observed during the first month of treatment. FT819 is the company's off-the-shelf, CD19-targeted, 1XX CAR T-cell product candidate comprised of CD8ass+ T cells with a memory phenotype and high CXCR4 expression to promote tissue trafficking. The ongoing multi-center, Phase 1 clinical trial for patients with moderate-to-severe SLE is designed to evaluate the safety, pharmacokinetics, and anti-B cell activity of FT819. The first three patients, all of whom presented with active LN despite having been treated with multiple standard-of-care therapies, received fludarabine-free conditioning consisting of either cyclophosphamide alone or bendamustine alone, followed by a single dose of FT819 at 360M cells. In all three patients, FT819 was detected in the peripheral blood and rapid, deep, and sustained elimination of CD19+ B cells in the periphery was observed during the first month of treatment. All three patients remain on-study, and there have been no DLTs and no events of any grade of CRS, ICANS, or GvHD. Based on these clinical observations, the company is initiating dose expansion in up to 10 patients at this first dose level, and is also escalating dose to 720M cells. The company's FT819 Phase 1 Autoimmunity study also includes a second treatment arm to assess the safety, pharmacokinetics, and anti-B cell activity of a single dose of FT819 as an add-on to maintenance therapy without conditioning chemotherapy in patients with SLE. The first patient has now been treated in this second arm, which is being conducted in parallel with the study's conditioning arm. The first patient treated in the Phase 1 Autoimmunity study presented with active LN and severe disease, which was marked by renal BILAG A disease activity score based on biopsy, SLEDAI-2K score of 20, FACIT-Fatigue score of 33 and PGA score of 2.5. Following administration of fludarabine-free conditioning and treatment with a single dose of FT819 at 360 million cells, the patient was discharged from the hospital without notable adverse events, or AEs, after a protocol-required three-day stay. Rapid elimination of CD19+ B cells in the periphery was observed following treatment, and B-cell recovery by Month 3 was predominantly comprised of naive, non-class switched B cells with near-complete elimination of switched memory B cells and deep depletion of plasmablasts, indicative of an immune reset. The patient reported that her debilitating fatigue had entirely resolved without further treatment, and treatment with methylprednisolone was discontinued at Month 3. The patient achieved DORIS clinical remission, including with resolution of arthritis and active urinary sediment and with a substantial reduction in proteinuria, as of Month 6 follow-up. The patient continues on-study, in DORIS clinical remission, and remains free of all immunosuppressive therapy. The company also highlighted the scientific progress of its proprietary iPSC-derived CAR T-cell product platform at the ASH Annual Meeting. In an oral presentation entitled "Off-the-shelf Product Candidate Incorporates Novel Sword & Shield Technology Designed to Promote Functional Persistence without Conditioning Chemotherapy", the Company compared its novel Sword & Shield technology, which utilizes a 4-1BB-targeted CAR alongside the complete knock-out of CD58 to both target and evade host alloreactive immune cells, to other host immune evasion strategies. In preclinical studies of allogeneic models, the Company showed that its Sword and Shield Technology specifically engaged with alloreactive T cells and supported functional persistence while avoiding the killing of general host T cells and activated anti-tumor T cells. This unique observation was not seen with other approaches that are either too broad and undesirably eliminate most of the host immune system or have limited coverage and cannot adequately protect the allogeneic cell product. In a second presentation entitled "Development of Induced Pluripotent Stem Cell-Derived T Cells Exhibiting Phenotypic and Functional Attributes of Primary CAR T Cells", the company conducted a series of high-resolution analyses to show stimulated iPSC-derived T cells elicit primary T-cell like activation, proliferation, transcriptional and functional program engagement, and iPSC-derived CAR T cells uniquely emulate antigen-mediated response similar to primary-derived autologous CAR T cells.

16:08 EST Container Store trading halted, news pending

16:06 EST Oracle reports Q2 Total Remaining Performance Obligations up 49% to $97B

16:01 EST Intuit, Amazon expand strategic partnership - Intuit (INTU) and Amazon (AMZN) announced a multi-year strategic partnership to empower millions of Amazon sellers to manage their finances, stay compliant, access capital, and grow their business. By leveraging Intuit's AI-driven expert platform, millions of Amazon sellers will be able to discover and access Intuit's platform seamlessly, benefiting from powerful financial insights like profitability, cash flow, and estimated tax liabilities to fuel their growth. QuickBooks will become Amazon's preferred partner for financial management solutions integrated directly in Amazon Seller Central, the Amazon site where sellers manage their businesses. "Intuit and Amazon are providing financial tools for millions of Amazon sellers to thrive in Amazon's store," said Intuit CEO Sasan Goodarzi. "We know businesses that use Intuit's QuickBooks platform have a nearly 20-point higher success rate than those who don't. We're proud to partner with Amazon to bring the benefits of our AI-driven expert platform to help sellers boost their revenue and profitability, save time, and grow with confidence."

15:03 EST Chanson International Holding trading halted, volatility trading pause

14:19 EST Zeta Global CEO says Omnicom, IPG announcement 'positive one for industry' - Zeta Global (ZETA) released a statement following Omnicom's (OMC) announcement that it has entered into a definitive agreement to acquire the Interpublic Group of Companies (IPG): "Earlier today, Zeta Global hosted its Zeta Data Summit, where among many other topics, David Steinberg, Zeta's Co-Founder, Chairman, and CEO, was asked about today's Omnicom and IPG news. David A. Steinberg, Co-Founder, Chairman, and CEO, said: 'Expanding on my earlier comments, we are proud of our extensive relationships with the top Holdcos, including both Omnicom and IPG, and believe that today's announcement is a positive one for the industry and Zeta. Like everyone else, we will be watching closely as this progresses and offer support as needed.'"

14:11 EST Sanofi says Sarclisa combos showed benefits in multiple myeloma patients - Sanofi says new data from three oral presentations demonstrated significant clinical benefit with Sarclisa-based quadruplets in newly diagnosed multiple myeloma patients. Sarclisa-VRd demonstrated a consistent benefit at every time point up to 60 months and led to the highest minimal residual disease negativity rate of a newly diagnosed multiple myeloma patient regimen with a bortezomib, lenalidomide and dexamethasone backbone, when evaluating exclusively transplant-ineligible patients, according to Sanofi. Higher minimal residual disease negativity rates were observed at both the end of initiation and during maintenance, with 58.1% of patients in the intention-to-treat population treated with Sarclisa-VRd achieving minimal residual disease negativity versus 43.6% of patients in the control arm, according to the company.

13:48 EST Disney CFO says will raise prices further on streaming services - Disney CFO Hugh Johnston says Disneyworld booking are still up for next summer, but the company "expects impact" to Disneyworld from the opening of the rival Epic Universe park. Johnston is participating in a question-and-answer session at the UBS Global Media and Communications Conference.

13:35 EST GSK says median overall survival not reached in multiple myeloma study - GSK announced "statistically significant and clinically meaningful" overall survival results from a planned interim analysis of the DREAMM-7 trial evaluating belantamab mafodotin in combination with bortezomib plus dexamethasone versus daratumumab in combination with bortezomib plus dexamethasone as a second line or later treatment for relapsed or refractory multiple myeloma. With a median follow up of 39.4 months, the analysis shows a statistically significant 42% reduction in the risk of death among patients receiving the belantamab mafodotin combination versus the daratumumab-based comparator, the company said in a statement). Although the median overall survival was not reached in either arm of the study, the projected median overall survival for bortezomib plus dexamethasone is 84 months compared to 51 months for bortezomib plus dexamethasone, it added. The three-year overall survival rate was 74% in the belantamab mafodotin combination arm and 60% in the daratumumab combination arm. The survival benefit favoring bortezomib plus dexamethasone was seen as early as four months and was sustained over time, according to GSK. Reference Link

13:14 EST T-Mobile CEO says Q4 'going great,' confident in guidance - T-Mobile CEO Mike Sievert, while presenting at the UBS Global Media and Communications Conference, stated according to a transcript of the event that the "good news is we recently reguided just a few weeks ago and said we'd be at 3 million or so postpaid phone net. I can tell you that that's looking we're very confident in that. It's been a great quarter so far. The only thing I would caution, and I can just hear myself saying this in prior years as well, is that this quarter's back end loaded. So while I'm here to tell you, it's going great, we're confident in our guidance, investors should be cautious because there's a lot of risk in the back half. Most of this quarter is still in front of us, if you will, because of the shaping of Q4 is a little different than most quarters, but we feel great about it."

13:01 EST Norfolk Southern appoints Ann Adams as CHRO - Norfolk Southern has named Ann Adams as Chief Human Resources Officer, with responsibility for human resources and labor relations, reporting to CEO Mark George. In addition, PC Bryant has been named Vice President Human Resources, reporting to Adams. Adams joined Norfolk Southern in 2001 as a Manager in Human Resources.

12:57 EST T-Mobile CEO says Q4 'back end loaded' with 'a lot of risk' - T-Mobile CEO Mike Sievert, while presenting at the UBS Global Media and Communications Conference, said the company's Q4 is "back end loaded" with "a lot of risk in the back half." The stock is down 5%, or $13.32, to $230.46 in afternoon trading.

12:43 EST Nippon Steel rebuts USW in letter to U.S. Steel employees - Nippon Steel (NPSCY) shared a letter to U.S. Steel (X) employees, saying in part: "We had hoped that continued discussions with the USW leadership would result in their support for the transaction. Our goal has been to listen to their concerns and to build on our commitments to spend $2.7 billion in capital investments at unionized facilities, share our world-class technological innovations, and secure union jobs so that American steelworkers at U. S. Steel can manufacture the most advanced steel products in the United States for American customers. During our recent discussions with the USW leadership, we listened carefully to the USW's requests for further details on our future plans....No less than $1 billion will be spent at Mon Valley Works...Approximately $300 million will be spent at Gary Works...Nippon Steel also intends to maintain the operation of all blast furnaces currently operating and to schedule six blast furnaces (two at Mon Valley and four at Gary) for relining or major repair by 2030 in order to extend their useful lives for many years to come." Reference Link

12:31 EST Poseida Therapeutics highlights interim Phase 1 results for P-BCMA-ALLO1 - Poseida Therapeutics will highlight interim clinical data from its Phase 1 trial of P-BCMA-ALLO1 in patients with relapsed/refractory multiple myeloma, including new profiling of patient responses from Arm C, an optimized lymphodepletion arm. The P-BCMA-ALLO1 data are being presented, along with two additional Company poster presentations covering new preclinical data for P-CD19CD20-ALLO1 and a patient case study demonstrating the reactivation of a Poseida autologous CAR-T therapy with a T-cell engager, at the 66th ASH Annual Meeting and Exposition being held in San Diego on December 7-10, 2024. P-BCMA-ALLO1 is an investigational non-viral, stem cell memory T cell-rich allogeneic CAR-T cell therapy in Phase 1/1b clinical development for the treatment of patients with RRMM. P-CD19CD20-ALLO1 is an investigational, non-viral TSCM-rich allogeneic CAR-T cell therapy in Phase 1 clinical development for the treatment of patients with B-cell malignancies and is the Company's first dual CAR-T program. P-BCMA-ALLO1 and P-CD19CD20-ALLO1 are being developed in collaboration with Roche. P-BCMA-ALLO1 Phase 1 Data: The poster presentation will highlight Phase 1 clinical data first presented at the 21st International Myeloma Society Annual Meeting in September 2024. The data showed a 91% overall response rate in Arm C, including a 100% ORR in B-cell maturation antigen-naive patients, and an 86% ORR in those who had received at least one prior BCMA- and/or G protein-coupled receptor class C group 5 member D-targeting treatment modality, along with differentiated safety results with no dose-limiting toxicities, low rates of cytokine release syndrome and immune effector cell neurotoxicity syndrome, all Grade 2 or less, and no graft vs. host disease or Parkinsonism. No patients required anti-myeloma bridging therapy or prophylaxis with steroids or tocilizumab, and there was no invasive apheresis; an average manufacturing wait time, from treatment decision to clinical response, was only 3.5 weeks. The patients in this study had more advanced disease than the myeloma patients studied in clinical trials of approved autologous CAR-T therapies, and in the intent-to-treat population, 100% of patients were infused with P-BCMA-ALLO1. New profiling of patient responses from Arm C are included in the ASH poster presentation. The data from this analysis show consistent P-BCMA-ALLO1 cellular expansion and persistence across different subgroups, including patients that are typically more challenging to treat. Key highlights suggest that P-BCMA-ALLO1: Cellular kinetics were not impacted by prior BCMA/GPRC5D-targeted therapy Expands and persists in patients with extramedullary disease P-CD19CD20-ALLO1 Preclinical Data Preclinical data has demonstrated that P-CD19CD20-ALLO1 delivers high in vitro potency and strong in vivo antitumor activity for either CD19 or CD20 single-positive target cells, as well as double-positive targets. New preclinical data included in the poster presentation show that compared to CD19-single targeting or CD20-single targeting CAR-T cells, P-CD19CD20-ALLO1: Achieved higher and more durable killing of tumor cells over three rechallenges, even in the presence of only one tumor antigen Exhibited higher cytotoxicity Produced higher and more sustained levels of effector cytokines that play an important role mediating the immune system response to cancers Showed higher in vivo antitumor efficacy than the CD19-single targeting CAR-T cells The Company's P-CD19CD20-ALLO1 Phase 1 clinical trial is enrolling patients with selected B-cell malignancies, with initial clinical data anticipated in 2025. CAR-T Reactivation with T-cell Engager Case Study The case study highlights the reactivation of an autologous Poseida CAR-T therapy with a T-cell engager in a patient with relapsed multiple myeloma. The patient attained and remained in stringent complete response over 12 months after CAR-T reactivation. This case highlights the potential of Poseida's TSCM-based CAR-T therapies to deliver a strong anti-myeloma response with long-term remission and CAR-T cell persistence. The Company believes this is the first time that a T-cell engager has been seen to reactivate a CAR-T therapy.

12:24 EST Crispr Therapeutics presents data on CTX112 at ASH Meeting - CRISPR Therapeutics presented data from the Company's ongoing Phase 1/2 dose escalation clinical trial evaluating the safety and efficacy of CTX112, a next-generation CD19 allogeneic CAR T cell therapy, in relapsed or refractory CD19-positive B-cell malignancies at the 2024 American Society of Hematology Annual Meeting. Additionally, the Company announced that the U.S. Food and Drug Administration granted Regenerative Medicine Advanced Therapy designation to CTX112 for the treatment of R/R follicular lymphoma and marginal zone lymphoma. The Phase 1/2 clinical trial is an open-label, multicenter study evaluating the safety and efficacy of CTX112 in relapsed or refractory B-cell malignancies. Eligible disease subtypes include large B-cell lymphoma, follicular lymphoma grade 1-3a, marginal zone lymphoma, and mantle cell lymphoma/ CTX112 was infused after a standard course of lymphodepleting chemotherapy. Data were presented from 12 subjects treated during the dose escalation with CTX112 doses ranging from 30 x 106 CAR+ T cells. The study population was enriched for patients with high-risk characteristics, including: primary refractory disease or early relapse to first-line therapy; high tumor burden; and high disease prognostic index score or elevated lactate dehydrogenase. CTX112 was well tolerated across all dose levels. There were no reported dose limiting toxicities and no reported Grade greater than or equal to3 infections. All grade 3 or 4 cytopenias following lymphodepleting chemotherapy resolved to Grade 2 or better within 1 month of CTX112 infusion. There were no reported cases of Graft versus Host Disease. All cases of cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome were Grade 1 or 2 per the American Society for Transplantation and Cellular Therapy criteria. Objective and complete responses were seen at all dose levels and in all treated NHL subtypes. Responses were also seen in patients with poor prognostic factors including primary refractory disease, early relapse, and high baseline tumor burden. Five patients have achieved responses lasting for more than 6 months, including one patient whose 6-month response was confirmed after the data cut-off date. One patient treated at DL1 remains in complete remission over a year after initial CTX112 infusion. The clinical efficacy of CTX112 is supported by a clearly differentiated pharmacokinetic profile for an allogeneic CAR T cell therapy. The mean peak concentration and total exposure were significantly higher at DL3 and DL4 vs. DL1 and DL2. This dose dependence suggests the possibility of deeper and more durable responses as the trial moves from dose escalation to dose optimization. Comparing DL3, the addition of Regnase-1 and TGFbetaR2 edits results in 7-fold higher peak concentration and 9.7-fold higher mean area under the curve for CTX112 relative to CTX110. Furthermore, at DL4, both Cmax and AUC are showing significantly more consistent and predictable increases. This suggests that the novel CRISPR/Cas9 potency edits are leading to higher CAR T cell expansion and functional persistence without enhanced or increased lymphodepleting chemotherapy doses. These preliminary data demonstrate that CTX112 has the potential to provide meaningful clinical benefit with a well-tolerated safety profile. Given the inherent difficulties of manufacturing a CAR T therapy from a patient's own diseased cells, allogeneic cellular therapy approaches have greater potential to address the unmet need in this patient population.

12:16 EST Disc Medicine presents clinical, translational data acroos portfolio at ASH meet - Disc Medicine spotlights 8 posters presented at the ASH 2024 annual meeting in San Diego, CA. This year's presentations included updates from the BEACON and AURORA trials of bitopertin in patients with erythropoietic protoporphyria and the Phase 1 SAD/MAD trial of DISC-3405 in healthy volunteers. Additionally, Disc presented a real-world patient survey highlighting the disease burden of EPP and multiple preclinical models highlighting the potential benefits of bitopertin, DISC-0974, and DISC-3405 in existing and new indications. The collection of data supports Disc's continued advancement of all three clinical candidates and provides evidence for expansion opportunities in new indications. In addition to its poster presentations, Disc presented complete results from the Phase 1b trial of DISC-0974 in anemia of myelofibrosis yesterday, December 8, in an oral presentation. These results demonstrated positive impact on clinically meaningful measures of anemia across a broad range of patient types and support advancement of the program into a Phase 2 trial in MF anemia, which is now initiated. Bitopertin, DISC-0974, and DISC-3405 are investigational agents and are not approved for use as therapies in any jurisdiction worldwide. Bitopertin: Disc is advancing development and registrational activities for bitopertin in EPP, with the potential for accelerated approval using PPIX as a surrogate endpoint. AURORA: The AURORA study is a randomized, double-blind, placebo-controlled Phase 2 clinical trial that enrolled 75 adult subjects with EPP. Subjects were randomized 1:1:1 to receive 20 mg of bitopertin 60 mg of bitopertin, or placebo orally once daily for 17 weeks. Updated analyses show that bitopertin reduced PPIX in all prespecified subgroups across demographic and baseline patient characteristics; Previously presented analyses showed that reductions in PPIX were associated with improvements in multiple clinical outcomes, including measures of sunlight tolerance, reductions in phototoxic reactions, and patient-reported quality of life. BEACON: The BEACON study is a Phase 2, randomized, open-label, multiple dose clinical trial that enrolled 22 adults and 4 adolescents with EPP. Subjects were randomized 1:1 to receive 20 mg of bitopertin or 60 mg of bitopertin orally once daily for 24 weeks. Updated analyses show that bitopertin significantly reduced protoporphyrin IX at low and high doses and in both adult and adolescent populations; Bitopertin had a meaningful impact on light tolerance, with similar benefit shown across adult and adolescent populations; Reductions in PPIX were associated with improvements in multiple measures of sunlight tolerance; Bitopertin was generally well tolerated and showed a similar safety profile in adults and adolescents. EPP LIGHT Study: The EPP LIGHT Study is a patient survey study seeking to comprehensively describe the burden of disease in adults and adolescents with EPP. Across adult and adolescent respondents, EPP symptoms impact all facets of life including ability to be out in the sun for prolonged periods of time, ability to undertake daily activities, deficits in emotional functioning, and absenteeism at work and school; 68% of adults and 45% of adolescents experienced pain from a phototoxic reaction after less than30 minutes in direct sunlight, and recovery time was an average of 5.5 +/- 4.8 days for adults and 5.1 +/- 3.0 days for adolescents; 75% of adults and 46% of adolescents reported feeling depressed or sad and respondents reported substantially lower satisfaction with social roles and higher feelings of social isolation than the general population; 23% of employed adults reported missing work in the past month due to EPP; 24% of adults and 42% of adolescents attending school at the time of the study reported missing school in the past month due to EPP. Phototoxicity Study in Mouse Model of EPP: The effects of an orally bioavailable glycine transporter 1 inhibitor, DISC-C, on PPIX levels and skin phototoxicity induced by UV/blue light were evaluated in EPP mice. Results showed: Treatment with a mouse analog of bitopertin caused a 37-40% decrease in PPIX levels in red blood cells; GlyT1 inhibition significantly reduced skin lesions after light exposure; treated mice developed skin lesions in 9.2% of exposed skin area vs. 51.2% in placebo; Percentage of area with skin lesions correlated with PPIX levels, supporting PPIX as the pathological driver of phototoxicity in EPP

12:11 EST Acadia down 1% following NY Times expose on 'fraud and fakery' at clinics - Shares of Acadia Healthcare are down 37c, or 1%, to $40.75 in Monday midday trading following the publications of a New York Times investigation over the weekend that alleged "fraud and fakery" found at Acadia Healthcare's chain of 165 methadone clinics.

12:04 EST Aptose Biosciences announces clinical data on tuspetinib - Aptose Biosciences featured a wealth of clinical data for Aptose's lead compound tuspetinib in a poster presentation at the 66th American Society of Hematology Annual Meeting in San Diego. Poster title: "Phase 1 Safety and Efficacy of Tuspetinib Plus Venetoclax Combination Therapy in Study Participants with Relapsed or Refractory Acute Myeloid Leukemia Support Exploration of Triplet Combination Therapy of Tuspetinib Plus Venetoclax and Azacitidine for Newly Diagnosed AML" Key Findings and Messages: TUS+VEN+AZA triplet trial is proceeding in newly diagnosed AML patients. TUS+VEN retains activity in the difficult-to-treat prior-VEN AML population. TUS+VEN is active in FLT3 wildtype, representing ~70% of AML patients. TUS+VEN is well tolerated and can be safely co-administered. TUS+VEN is active across broad populations of R/R AML. Combination of TUS with VEN may avoid VEN resistance. TUS+VEN+AZA triplet may establish a more effective, mutation agnostic standard of care for chemotherapy ineligible AML patients. Tuspetinib, being developed by Aptose and originally created by Hanmi Pharmaceutical Co., is being advanced as the TUS+VEN+AZA triplet for frontline therapy of newly diagnosed AML patients ineligible for intensive chemotherapy. TUS is a once daily, oral, multi-kinase inhibitor selectively targeting kinases that drive AML cell proliferation. In the Phase 1/2 APTIVATE trial of relapsed/refractory AML patients, TUS single agent and the TUS+VEN doublet demonstrated excellent safety and broad efficacy across AML genetic subgroups - including those with adverse mutations in TP53 and RAS genes, and those with mutated or unmutated FLT3 genes. Highlights of the ASH poster presentation: TUS as Single Agent: 60% and 42% CR/CRh with 80 mg TUS in FLT3 mutated and all-comer VEN-naive AML 33% CRc & 42% ORR in FLT3 mutated and VEN-naive patients. Includes 40, 80, 120, and 160 mg TUS dose as a single agent. Includes those who failed prior therapy with venetoclax. Includes those with mutated or unmutated FLT3, those who failed prior-HSCT, priorFLT3i, prior-chemotherapy, prior-HMA. TUS once daily orally as a single agent achieved CR/CRh responses at four different dose levels with no dose limiting toxicities. TUS showed a favorable safety profile with no DLTs through 160 mg per day, and no drug related discontinuations, no QTc, no differentiation syndrome, and no deaths. TUS/VEN Combination Therapy: 40% ORR with 80 mg TUS + 400 mg VEN in FLT3 mutated patients. Among these 83% had failed prior-VEN treatment and 50% had failed both prior-VEN and FLT3i treatment. TUS+VEN achieved responses among diverse R/R AML with adverse mutations in VEN-naive, prior-VEN, FLT3WT, FLT3MUT, prior-FLT3. TUS+VEN showed favorable safety and tolerability with no new or unexpected safety signals, no drug related CPK elevations, no differentiation syndrome, and no deaths

KE Holdings is up 16.3%, or $3.08 to $21.89.

Direxion Daily Gold Miners Bear 3X ETF is down -9.9%, or -$6.01 to $54.80.

Sweetgreen is down -11.7%, or -$4.90 to $37.14.

11:34 EST Zentek regains Nasdaq compliance - Zentek received a written notification from the Nasdaq Stock Market that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), as the minimum bid price of the Company's common stock has been above $1.00 per share for the last 11 consecutive business days.

11:19 EST CN reaches tentative collective agreement with Unifor - CN announced a new tentative four-year collective agreement has been reached with Unifor. The union represents approximately 3,300 employees at CN in Canada, working in different mechanical, clerical, and intermodal functions. No details of the tentative agreement will be released publicly until the agreement is ratified. The current collective agreement with Unifor expires on December 31, 2024.

11:04 EST Veon launches initial $30M phase of share buyback program - VEON's Board of Directors has approved the commencement of the first phase of its previously announced share buyback program with respect to the Company's American Depositary Shares. This first phase of the buyback will be in the amount of up to $30M. This $30M first phase is part of VEON's larger plan to execute a share buyback program of up to $100M. The buybacks will be conducted on the open market pursuant to a 10b5-1 plan signed with a registered broker-dealer, and in compliance with Rule 10b-18.

10:18 EST Comcast Cable CEO sees Q4 broadband subscriber loss of just over 100,000 - Comcast Cable CEO says hurricanes will impact about 10,000 broadband losses in Q4. Comcast Cable CEO says competition remained "intense" in Q4. Comcast is presenting at the UBS Global Media & Communications Conference. During the presentation, shares of are down about 6% to $40.70. Reference Link

10:10 EST Hershey trading resumes

10:06 EST Mondelez made preliminary approach Hershey, Bloomberg reports

10:04 EST Mondelez partners with ISN to expand contractor management - ISN has selected ISNetworld as its primary contractor information management system for the Give & Go business unit. ISN will help Mondelez streamline contractor safety and compliance through contractor oversight, training, compliance tracking, and performance evaluations.

10:01 EST BAE Systems unit awarded $12M contract from DARPA - The U.S. Defense Advanced Research Projects Agency has awarded BAE Systems' FAST Labs research and development organization a $12M contract as part of the High Operational Temperature Sensors program. The HOTS program will help develop microelectronic sensor technologies capable of high-bandwidth, high-dynamic-range sensing at extreme temperatures. Under the terms of the contract, BAE Systems will design and build a new pressure sensor module - consisting of an integrated transducer and signal-conditioning microelectronics - able to operate with high performance at 800 degrees C or 1,472 degrees F. Work on this program will take place at BAE Systems' facilities in Nashua, New Hampshire and Merrimack, New Hampshire. It will also include collaboration with subcontractors The Penn State Applied Research Laboratory, Purdue University and Kampanics, LLC, and supplier GE Aerospace's research center.

Titan International is up 21.6%, or $1.50 to $8.45.

Archer Aviation is down -6.3%, or -52c to $7.76.

Direxion Daily Gold Miners Bear 3X ETF is down -9.4%, or -$5.71 to $55.10.

09:53 EST Macy's rallies after activists provide shareholder value recommendations - Barington Capital and Thor Equities, who are shareholders of Macy's, earlier today published a presentation recommending that Macy's make changes to its capital allocation strategy and consider other structural actions to improve shareholder value. "Due to long-term challenges in the department store sector and previous management missteps, Macy's valuation has suffered markedly over the past decade with its shares down approximately 70%. Despite numerous attempts at implementing strategic plans under multiple leadership teams to overhaul Macy's value proposition, the one constant of all these ineffective actions has been Macy's reliance on spending enormous amounts of the Company's cash flows on capital expenditure projects...Barington and Thor propose that Macy's consider the following recommendations to improve shareholder value: Reduce capital expenditures to 1.5%-2% of total sales from ~4% currently; Repurchase a minimum of $2-$3 billion in stock over the next three years; Create a separate internal real estate subsidiary to optimize the return potential of the Company's valuable owned real estate assets; Evaluate strategic alternatives for the Company's higher growth Bloomingdale's and Bluemercury luxury operations; and add Barington and Thor representatives to the Macy's board." Shares of Macy's are up 4% to $17.09 in early trading.

KE Holdings is up 12.3%, or $2.31 to $21.13.

09:48 EST zSpace, Inc. trading halted, volatility trading pause

Omnicom is down -5.7%, or -$5.89 to $97.53.

Direxion Daily Gold Miners Bear 3X ETF is down -8.2%, or -$4.97 to $55.84.

09:38 EST DESTINY TECH100 INC trading resumes

09:36 EST RADX Stock trading resumes

09:33 EST Mobileye releases presentations for Capital Markets Day in Germany - Mobileye released the slides for presentations given at the December 9 Capital Markets Day being held in Munich, Germany. "They are meant to be viewed in combination with the verbal presentations given by the Mobileye management team that can be accessed through the replay that will be provided after the event," the company stated. Reference Link

09:32 EST Barnes & Noble Education 'believes it can drive meaningful operating' FCF - The company said, "Barnes & Noble Education is focused on driving material improvements in its profitability and further improving its already strong financial foundation. Management is working on simplifying its operations to better focus on its core physical and virtual bookstore businesses. Go-forward savings from recently completed and in-progress initiatives are now estimated at over $20 million. The Company recently completed a $40 million At-the-Market sales agreement with BTIG, LLC. The proceeds of this capital raise will reduce go-forward annual interest expense by nearly $4 million per year, reduce risk, accelerate our ability to win new customers, and enhance our strategic and balance sheet optionality. In the medium-term, management is seeking to reduce annual interest expenses to around $10 million or less. The Company's budget goals continue to target a material improvement in fiscal year 2025 GAAP operating results and Adjusted EBITDA versus last year. Based on current estimates of capital expenditures and significantly reduced interest costs from last fiscal year, BNED believes it can drive meaningful operating free cash flow, which will be used to further de-lever its balance sheet."

09:30 EST Rent the Runway trading halted, volatility trading pause

09:22 EST LTC Properties names Wendy Simpson chairman, Pam Kessler and Clint Malin co-CEOs - LTC Properties announced that Wendy Simpson has been appointed executive chairman of board of directors, Pam Kessler and Clint Malin have been promoted to co-CEO, and Cece Chikhale has been promoted to CFO. The appointments are part of the company's succession plan and are effective December 31. The company said it is conducting a search for a new chief investment officer to succeed Clint Malin, who will retain that function until a successor is named.

09:17 EST Artelo presents Phase 1 data with ART27.13 in cancer-related anorexia - Artelo Biosciences announced the presentation of preliminary data on ART27.13, the Company's benzimidazole derivative, being studied for cancer-related anorexia. The data was presented by the Principal Investigator, Professor Barry J. A. Laird, Chair of Palliative and Supportive Care, University of Edinburgh and Consultant Physician in Palliative Medicine, Edinburgh Cancer Centre, at the 17th International Conference on Sarcopenia, Cachexia, & Wasting Disorders, held December 6-8, 2024 in Washington D.C. Artelo is evaluating ART27.13 in the Cancer Appetite Recovery Study, a randomized, placebo-controlled Phase 1/2 trial in cancer-related anorexia, which is currently enrolling the Phase 2 of the study. In the Phase 1 of CAReS, ART27.13 was orally administered at 150 to 650 microgram doses in multiple centers throughout the UK and Ireland. The investigational drug was well tolerated with only mild to moderate adverse events observed in a minority of participants. No serious or life-threatening adverse events were recorded. Importantly, at one month of treatment, two-thirds of participants showed evidence the drug was impacting their weight loss with either stabilization or reversal of weight loss associated with their cancer. Open to enrollment in fifteen sites across five countries, the Phase 2 of CAReS is accruing participants at a 650 microgram dosage with planned escalation at 4-week intervals up to a dose of 1300 micrograms per day. In CAReS, all participants receive ART27.13 once-daily for up to 12 weeks and the endpoints include lean body mass, weight gain, quality of life and safety. The Phase 2 portion will also evaluate any impact on activity levels using a monitor attached to the patient's wrist. The study is expected to complete enrollment during the first half of 2025.

09:15 EST Lexaria Bioscience engages CRO for human pilot study of DehydraTEHC-liraglutide - Lexaria Bioscience announced the engagement of a contract research organization to design and execute a human pilot study evaluating DehydraTECH-liraglutide against Saxenda injectable liraglutide. As reported on November 20th in Lexaria's 12-week rodent study with unlimited food available, DehydraTECH-processed liraglutide - administered orally - demonstrated a 5.88% weight reduction and 11.54% blood sugar reduction compared to baseline. The Rybelsus control, which was expected to outperform liraglutide, instead produced a 5.65% increase in body weight and 0.41% blood sugar reduction compared to baseline during the same 12 weeks. As a result of the stronger than expected performance of DehydraTECH-processed liraglutide, the Company has made the decision to investigate further with human study GLP-1-H25-5 expected to be conducted with 8-10 healthy volunteers. The goal of the Study will be to demonstrate safety and test pharmacokinetic performance in humans with an oral version of DehydraTECH-processed liraglutide. If positive, it could support a future decision to investigate DehydraTECH-liraglutide in a future Phase I registered trial. Development of the Study protocol is underway and Lexaria and the CRO are evaluating options for selection of the clinical site and jurisdiction in which to perform this Study, which has not yet been determined. Further updates will be provided in due course when Lexaria has obtained the necessary ethics board approval before the Study can begin.

09:09 EST Nitches, Inc. announces growth in InTheZone Labs' affiliate program - Nitches announced growth in InTheZone Labs' affiliate program. The company said, "Over the past weekend, we onboarded more than 25 new affiliates through ShareASale and the Awin network. This expansion enhances our ability to connect with a broader audience and aligns with our mission of delivering premium nutraceutical products to consumers worldwide. We are thrilled to announce that InTheZone Labs has partnered with Honey by PayPal, a leading online savings platform with a community of over 29 million members globally. Our store is now live on Honey's website, offering exclusive deals to their vast user base. Integration is currently underway, and full functionality is expected in the coming days. This collaboration marks a pivotal moment for InTheZone Labs as we join forces with a platform renowned for its innovation and reach. Honey was acquired by PayPal in January 2020 for $4 billion, making it PayPal's largest acquisition to date...InTheZone Labs is excited to announce that we have received approval from Amazon Selling Partner Support to list our products across all Amazon stores globally. Currently, we are integrating inventory and customizing product pages. Listings are pending compliance checks, and we look forward to providing updates as soon as our products are officially live on Amazon."

09:07 EST Freight Technologies selected by Nestle Mexico to provide logistics services - Freight Technologies (FRGT) announced that global food and beverage leader, Nestle Mexico (NSRGY), has selected Fr8App to support its domestic logistics operations. Javier Selgas, CEO of Fr8Tech, stated, "We are honored to have been selected by Nestle Mexico for such an important role in servicing their vital logistics operations. This significant achievement is the result of our ongoing dedication to safety, reliability, and proficiency across our offerings, as well as our capacity to meet the rigorous quality standards and high levels of customer service expected from respected global leaders, such as Nestle. Our team is excited to support the success of Nestle's domestic logistics operations and is fully prepared to meet and exceed their expectations."

09:06 EST WidePoint partners with 22Vets Technologies for Smart City IoT program - WidePoint announced a new contract award in partnership with 22Vets Technologies. WidePoint will deliver Non-Federal Issuer for PIV-Interoperable credentials in support of a global energy service company's new Smart City Internet of Things program.

09:06 EST GeoVax Labs receives Notice of Allowance for cancer vaccine patent - GeoVax Labs announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for Patent Application No. 17/876,682 to GeoVax, titled "Vaccinia Viral Vectors Encoding Chimeric Virus Like Particles." The allowed claims add to GeoVax's intellectual property protection related to its vector platform for expressing a tumor associated antigen, TAA, in virus-like particles, VLPs, from a recombinant Modified Vaccinia Ankara, MVA, viral vector, further demonstrating the GeoVax technical expertise.

09:04 EST Net Power, California Resources sign MOU to develop power solutions in CA - California Resources (CRC) and its carbon management business, Carbon TerraVault, announced the signing of a Memorandum of Understanding, MOU, with Net Power Inc. (NPWR), to develop Net Power's ultra-low emission power plants in California, CA. Under the terms of the MOU, the parties plan to conduct feasibility studies on locating Net Power's facilities in proximity to CTV's underground storage vaults, which would reduce carbon dioxide transportation costs and midstream investments for CTV's operations. The parties plan to facilitate the initial deployment of up to 1 gigawatt of power capacity from Net Power's new modular plants in Northern California, resulting in up to 3.6 million metric tons per annum of CO2 emissions for permanent sequestration in CTV's nearby reservoirs. Each of Net Power's utility-scale modular plants is expected to require less than 20 acres, generate up to 250 megawatts, and be deployable in multi-plant configurations.

09:03 EST Perpetua Resources announces continued cooperation with U.S. Antimony - Perpetua Resources (PPTA) announced its wholly owned subsidiary, Perpetua Resources Idaho, has agreed to conduct metallurgical testing of antimony concentrate samples from Perpetua's Stibnite Gold Project with Montana-based United States Antimony (UAMY). The Stibnite Gold Project has an antimony reserve of 148M pounds, making it one of the largest reserves of antimony not under Chinese influence and the only U.S. domestic reserve. The Project is expected to supply about 35% of total U.S. antimony demand in the first six years of operations, based on the 2023 USGS antimony commodity summary.

09:02 EST Crown Electrokinetics plans to build, co-own reverse osmosis plant in Mexico - Crown Electrokinetics announced that its Water Solutions division plans to construct and co-own a state-of-the-art reverse osmosis, RO, water treatment plant in Cabo San Lucas, Mexico for the desalination of water collected from its proprietary design slant wells. The new RO plant will be built and owned in partnership with locally based, 529 Capital, a leading real estate development firm in the Baja Peninsula. Together, they will provide a new reliable supply of clean, safe drinking water to the region.

08:59 EST Boliden to buy Neves-Corvo, Zinkgruvan mines from Lundin for up to $1.52B - Lundin Mining (LUNMF) has signed a definitive agreement to sell its Neves-Corvo operation in Portugal and Zinkgruvan operation in Sweden to Boliden (BDNNY) for up to $1.52B in total consideration. Under the terms of the agreement, Lundin Mining will receive upfront cash consideration of $1.37 billion upon closing, based on a cash-free and debt-free enterprise value of $1.3 billion as of an August 31, 2024 lock box date. In addition, Lundin Mining will receive up to $150 million in contingent cash consideration upon satisfaction of certain conditions outlined below. The Transaction is not subject to shareholder approval or any financing conditions. The proceeds from the Transaction will strengthen the Company's balance sheet and support its growth plans in the Vicuna District. Boliden has agreed to acquire 100% of the shares of Somincor-Sociedade Mineira de Neves-Corvo and 100% of the shares of each of Zinkgruvan Mining Aktiebolag and North Atlantic Natural Resources Aktiebolag from subsidiaries of Lundin Mining for up to $1.52 billion in cash, consisting of $1.37 billion in upfront cash consideration at closing and up to $150 million in contingent consideration. Total consideration at closing may also be subject to other customary adjustments in the event of non-permitted leakage from the Lock-Box. The terms of the agreement incorporate a Lock-Box completion mechanism, with the purchase price based on a cash-free and debt-free enterprise value of $1.3 billion, and assuming a normalized level of working capital. Based on the Lock-Box financial statements as of August 31, 2024, the upfront cash consideration to be paid at closing is $1.37 billion. The upfront cash consideration will also accrue interest at a 5% annual interest rate from August 31, 2024 to closing and is payable to the Company at closing. Neves-Corvo Contingent Payment Up to $100 million in contingent payments at Neves-Corvo is tied to underlying copper and zinc prices. Boliden will pay Lundin Mining 60% of the incremental revenue realized in each of the three calendar years between 2025 and 2027 where the average realized price on a semi-annual calendar period exceeds $4.50/lb copper and/or $1.30/lb zinc as per the London Metal Exchange reference prices. Incremental revenue is calculated using total payable sales volumes of copper and/or zinc for the semi-annual calendar period and tax affected using Portugal's current corporate income tax rate. Zinkgruvan Contingent Payment Up to $50 million in contingent payments at Zinkgruvan is tied to underlying zinc prices. Boliden will pay Lundin 50% of the incremental revenue realized in each of the two calendar years between 2025 and 2026 where the average realized zinc price on an annual calendar year exceeds US$1.40/lb zinc, as per the LME reference prices, provided a minimum annual production of 135 million pounds of payable zinc is achieved. Incremental revenue is calculated using total payable sales volumes of zinc for an annual calendar year period and tax affected using Sweden's current corporate income tax rate. The Zinkgruvan Contingent Payment is subject to a maximum payout of $25 million per calendar year. Indicative Timeline The Transaction is anticipated to close in mid-2025, subject to the completion of customary conditions and regulatory approvals, including but not limited to merger control approvals by the EU Commission and approval of the Swedish Inspectorate of Strategic Products under the Swedish FDI Act, and the change of control approval by the Portuguese Directorate-General for Energy and Geology under the Neves-Corvo Concession Contract.

08:56 EST Comcast, Warner Bros. Discovery announce multi-year distribution pact in Ireland - Comcast (CMCSA) and Warner Bros. (WBD) announced long-term agreements that will deliver WBD's portfolio of content to Xfinity and Sky UK and Ireland customers using Comcast's global technology platform across linear television, apps, and streaming services. Comcast has entered into renewal agreements that further the companies' longstanding distribution relationship with WBD's portfolio of linear cable networks for Xfinity TV customers, including TNT, TBS, CNN, Discovery, Food Network, HGTV, TLC, and Investigation Discovery. In addition, the agreements provide continued carriage of HBO and expand Comcast's rights to package the ad-supported versions of Max and Discovery+ in its streaming bundles. Comcast will also continue to offer WBD content as part of its U.S. NOW TV streaming services. The companies also announced that Sky UK and Warner Bros. Discovery have broadened their collaboration to bring Warner Bros. Discovery television and movies to Sky UK and NOW customers through a new long-term partnership in the UK and Ireland. The agreement will now include a new, non-exclusive ad-supported Max app when WBD launches the service in the UK and Ireland in early 2026. The Max ad-supported service will be bundled for Sky UK and Ireland customers, providing highly anticipated new shows on the service and more WBD content complementing Sky's position in seamless aggregation. In addition, NOW UK and Ireland Entertainment members will also receive bundled access to the ad-supported version of Max integrated into Sky's NOW experience alongside other top content. Financial terms of the agreements were not disclosed.

08:50 EST Northeast Bank commences ATM offering of voting common stock - Northeast Bank has entered into an equity distribution agreement with Piper Sandler & Co. and Keefe, Bruyette & Woods for the offer and sale from time to time of shares of its voting common stock having an aggregate offering price of up to $75,000,000.00 in an at-the-market offering. All of the Shares to be sold in the offering will be offered by the Bank. The Bank intends to use the net proceeds from the offering for general corporate purposes, including the support of additional growth. The Shares will be offered through Piper Sandler and KBW, as the distribution agents. Sales of the Shares, if any, will be made from time to time in negotiated transactions at market prices prevailing at the time of a sale or at negotiated prices, or as otherwise agreed with the distribution agents, and, as a result, sale prices may vary. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.

08:47 EST Sellas Life Sciences reports OS, ORR data from Phase 2 trial of SLS009 - SELLAS Life Sciences Group announced additional data from the expansion cohorts in the Phase 2 trial of SLS009, a highly selective CDK9 inhibitor, in relapsed/refractory acute myeloid leukemia. Key Highlights from the updated topline data: As of December 4, 2024, data cutoff, 14 patients were enrolled in Cohort 3 and 14 in Cohort 4 and 5, of which 9 were evaluable at the time of analysis. At latest follow-up, the mOS has not been reached yet but has exceeded 7.7 months in Cohort 3. This is particularly significant as the expected mOS for patients in this setting is typically 2.5 months. In expansion cohorts 4 and 5, in patients with AML-myelodysplasia-related changes with ASXL1 mutation and mutations and cytogenic changes other than ASXL1 the ORR was 56% in 9 evaluable for efficacy patients. SLS009 was well-tolerated with no new safety signals observed to date as the regimen remains safe in additional patients enrolled to date. The Phase 2 clinical trial of SLS009 is an open-label, single-arm, multi-center study designed to evaluate the safety, tolerability, and efficacy of SLS009 in combination with venetoclax and azacitidine at two dose levels, 45 and 60 mg. In the 60 mg dose cohort patients were randomized into either a 60 mg dose once per week or a 30 mg dose two times per week. The trial was expanded to include two additional cohorts, one with ASXL1 mutated AML patients and one with patients with myelodysplasia-related molecular abnormalities other than ASXL1. In addition to response and survival analyses, the study aims to identify biomarkers for the target patient population and enrichment for further trials.

08:41 EST Taoping signs non-binding letter of intent to acquire 100% of Yunti - Taoping announced that it has signed a non-binding letter of intent to acquire 100% of the equity of Shenzhen Yunti Internet of Things Co., Ltd., a Chinese company based in Shenzhen, Guangdong Province. Taoping's acquisition of Yunti, if consummated, is expected to open new revenue growth opportunities for the company, while further consolidating and expanding the company's market share in the lucrative elevator equipment and service industry. Under the letter of intent, Yunti's shareholders agree to transfer their ownership of Yunti to the company in exchange for newly issued ordinary shareholders of the company. The final valuation and timeline of the acquisition will be determined based on a mutually agreed upon independent third party's comprehensive evaluation of Yunti. The parties expect to close and integrate the acquisition over the next 12 months. The non-binding letter of intent does not create an obligation on the part of either party to consummate any transaction. The proposed transaction is subject to a definitive agreement to be negotiated between the parties, conditioned upon further financial and legal due diligence and approval of the company's Board of Directors, as well as other customary closing conditions, such as any required regulatory approvals. There is no assurance that any transaction will be concluded.

08:41 EST Forum Energy announces $75M share repurchase pact, sale-leaseback deals - Forum Energy Technologies announced that its Board of Directors has authorized a program for the repurchase of outstanding shares of FET's common stock having an aggregate purchase price of up to $75M. ...In addition, it may be executed using open market purchases pursuant to Rule 10b-18 under the Securities Exchange Act of 1934, as amended, in privately negotiated agreements pursuant to Rule 10b5-1 plans or other transactions...In the fourth quarter, FET completed sales of two manufacturing facilities located in Texas. Net proceeds totaled approximately $20M. The properties remain an integral part of FET's operations and long-term lease agreements were executed in connection with the transaction.

08:39 EST Post Holdings reports avian influenza at third-party contracted facility - Post Holdings provided information regarding an avian influenza incident at one of Michael Foods' third-party contracted egg-laying facilities. Post also affirmed its non-GAAP Adjusted EBITDA guidance for fiscal year 2025. A Michael Foods third-party contracted egg-laying flock in Iowa tested positive for avian influenza. The facility houses approximately 4.5M egg-laying hens, or approximately 12% of Post's controlled supply, inclusive of owned and third-party contracted farms.

08:38 EST Solitario announces drilling results from Golden Crest Project - Solitario Resources announced its "most compelling drilling results to date" on its Golden Crest Project. Significant gold mineralization was intersected over a substantial thickness in the lower Deadwood rock formation in drill hole GC-008. The entire lower Deadwood formation was mineralized with an average gold grade of approximately 1.0 gram per tonne over its entire 41.0-meter length. Importantly, gold grades were increasing with depth, with the last two meters of core averaging 3.4 gpt, the highest grades encountered before the hole was terminated due to technical drilling difficulties. The lower Deadwood formation hosts the majority of Tertiary gold mineralization in the historic Homestake-Wharf gold district situated several miles east of Solitario's land position. GC-008 represents the first mineralization ever discovered in Lower Deadwood outside of the historic district. Chris Herald, CEO, stated: "I cannot overstate the importance of these assay results. GC-008 represents a new Wharf-style discovery and is our most significant gold intercept to date. GC-008 was our first drill hole to test a major structural zone that has been traced on Solitario's property position well over 12 kilometers in length and approximately 500 meters wide. This exceptionally large structural/stratigraphic zone appears to be a very fertile mega-target that only has one drill hole and is open ended in all directions, including depth. This structural zone is suspected to have deep roots and is believed to be an important conduit to Tertiary-aged gold mineralization. GC-008 was designed to test this zone at the most receptive stratigraphic horizon - the lower Deadwood Formation. The historic Wharf district has an estimated total gold endowment of over 10 million ounces. Approximately half of this endowment occurred as high-grade mineralization, often over an ounce per tonne, and the other half was lower grade averaging about a gram per tonne. The lower grade mineralization formed a large halo around the higher-grade structures. We believe this intercept represents the lower-grade halo surrounding potentially high-grade structures."

08:36 EST PTC names Robert Dahdah as Chief Revenue Officer - PTC (PTC) announced that it has appointed Robert Dahdah as Executive Vice President, Chief Revenue Officer. Dahdah joins PTC from Microsoft (MSFT), where he served as Corporate Vice President of Global Healthcare and Life Sciences. Dahdah will be responsible for global sales and customer success for PTC's Digital Thread group and the overall execution of the company's vertical-focused go-to-market strategy.

08:35 EST Safety Shot announces Sure Shot now available on leading e-commerce platform - Safety Shot announced that its innovative alcohol-reducing dietary supplement, Sure Shot, is now available for purchase on the online store of a leading e-commerce platform. This platform is owned and operated by one of the largest big-box stores in the US, boasting a massive online presence and extensive distribution network. This expansion into the digital marketplace marks a significant step in Safety Shot's growth strategy, broadening its reach and providing consumers with greater accessibility to its products.

08:34 EST PodcastOne launches 'PodcastOne Pro' - PddcastOne (PODC), a subsidiary of LiveOne (LVO), has officially launched PodcastOne Pro, a full service solution that specializes in transforming podcasts into polished on-air productions for brands and professionals. PodcastOne Pro offers customizable services, with a la carte options to meet exact production needs, or a full 360 degrees solution. Services include access to top-of-the-line podcasting studios and equipment, strategy, program production, editing, guest booking, distribution, paywall options and promotion across PodcastOne's existing network of podcasts.

08:34 EST Carisma Therapeutics announces restructuring, 34% workforce reduction - Carisma Therapeutics announced a strategic reprioritization of its pipeline, cessation of development of CT-0525, and a reduction in the workforce by 34%. These measures will enable Carisma to focus its resources on advancing its in vivo macrophage engineering platform for the development of fibrosis, oncology and autoimmune disease therapies. This decision aligns Carisma's efforts with next-generation, high-potential programs addressing significant unmet patient needs while enhancing operational efficiency. "Following a comprehensive review of our portfolio, we have made the strategic decision to prioritize advancing our in vivo macrophage engineering platform," said Steven Kelly, President and Chief Executive Officer of Carisma. "The compelling data generated by both the Moderna-partnered in vivo CAR-M oncology programs as well as our internal liver fibrosis program underscore the potential to revolutionize treatment paradigms with an innovative and patient-centric approach." "These strategic initiatives, re-directing our investments to the in vivo macrophage engineering platform, discontinuing development of our anti-HER2 program and reducing our workforce, aim to streamline our operations and reduce operating expenses over time," Kelly continued. "While these decisions are very challenging, they are made in the best interest of our shareholders. We remain deeply grateful for the significant contributions of the employees departing Carisma." As part of the strategic restructuring, Carisma will reduce its workforce by 34%. The company expects the reduction in workforce to be substantially complete and to pay the majority of related reduction in workforce amounts by the end of the first quarter of 2025. The company is committed to supporting affected employees through this transition. As part of the workforce reductions, our Chief Financial Officer, Richard Morris, our General Counsel, Eric Siegel, and our Senior Vice President, Human Resources, Terry Shields, will leave the company effective December 31, 2024. Carisma expresses gratitude for their contributions. The company expects to incur approximately $2.7M in connection with the reduction in the workforce, which primarily represents one-time employee termination benefits directly associated with the workforce reduction.

08:33 EST NRSInsights reports November same-store sales increased 6.6% year-over-year - As of November 30, 2024, the NRS retail network comprised approximately 33,600 active terminals nationwide, scanning purchases at approximately 29,200 independent retailers including convenience stores, bodegas, liquor stores, grocers, tobacco, and sundries sellers nationwide, predominantly serving urban consumers. Same-store sales increased 6.6% year-over-year. In the previous month, same-store sales had increased 3.7% year-over-year. Same-store sales increased 1.5% compared to the previous month. Same-store sales in October 2024 had decreased (0.5)% compared to the previous month. For the three months ended November 30, 2024, same-store sales increased 3.5% compared to the corresponding three months a year ago. The number of units sold increased 4.5% year-over-year. In the previous month, the number of units sold had increased 2.8% year-over-year. Units sold decreased (0.4)% compared to the previous month. Units sold in October 2024 had decreased (0.5)% compared to the previous month. The average number of transactions per store increased 3.2% year-over-year. In the previous month, transactions had increased 1.6% year-over-year. Transactions decreased (2.5)% compared to the previous month. Transactions in October 2024 had decreased (0.7)% compared to the previous month.

08:30 EST BIO-key announces new passwordless options at 2024 Gartner IAM Summit - BIO-key was proud to be recognized in two Gartner reports in the past twelve months. Both reports emphasize the importance of adopting passwordless authentication to mitigate security risks. To support organizations in their journey to passwordless, BIO-key has introduced additional options with its MobileAuth offering, demonstrating its commitment to secure and user-friendly authentication solutions. BIO-key's MobileAuth biometric options include PalmPositive and FacePositive, which protect users from identity fraud and unauthorized access. Once biometrics are registered, only the authorized user can authenticate, significantly reducing the risk of fraud. Unlike Apple Touch ID or Face ID, which allow multiple users to register on a device, MobileAuth restricts access to a single authorized user for apps managed by the PortalGuard IDaaS solution. This ensures that no other users, "SIM-swappers," or hackers with phished credentials can gain access-only the intended user can authenticate. BIO-key also supports push-token and on-device biometrics for those users where convenience is more important than security.

08:28 EST CareCloud files special meeting proxy to accelerate growth - CareCloud announced the solicitation of proxies from its common stock shareholders to approve an increase in its authorized shares. This increase is designed to support the Company's growth initiatives and corporate objectives. The board-supported proposal seeks to increase the Company's authorized shares of Common Stock from 35 million to 85 million. This increase is intended to provide the flexibility needed for strategic growth initiatives, including future acquisitions, and to enable the potential conversion of the Company's outstanding Series A Preferred Stock to Common Stock. Additionally, it supports investments in organic growth and other corporate priorities.

08:27 EST BIT Mining completes first phase of acquisitions in Ethiopia - BIT Mining Limited announced that it has completed the first phase of previously-announced acquisition of crypto mining data centers and Bitcoin mining machines in Ethiopia. To complete the first phase of the acquisition, the company has made a cash payment of $2.265M and issued an aggregate number of 369,031,800 Class A ordinary shares to the sellers in exchange for a 35-megawatt operational and electrified crypto mining data center and 17,869 BTC mining machines. The second phase of the acquisition, which involves transfer of the remaining data centers to the company, will close upon completion of construction of the remaining data centers, which is expected to occur in March or April 2025. Upon closing of the second phase, the company will issue an additional 45,278,600 Class A ordinary shares as consideration.

08:27 EST Lifeist Wellness announces 'Mikra Wellness Giveaway' Holiday Campaign - Lifeist Wellness' Mikra Cellular Sciences is launching a marketing initiative for the holiday season: The Mikra Wellness Giveaway. Mikra's latest campaign, designed to reward loyal customers and drive new customer acquisition, will run from today, December 9, 2024, to January 15, 2025, and include those purchases of Mikra's scientifically formulated supplements made on wearemikra.com. Mikra's holiday promotion provides a unique opportunity for customers to celebrate the season of giving by sharing their Mikra experience with family, friends, and their social networks. Participation in the campaign is simple, visit wearemikra.com: Purchase Mikra products: Every purchase made during the campaign period will automatically earn customers an entry into the giveaway. Share on social media: Sharing Mikra-related posts on social platforms increases participants' chances of winning. Refer family, friends, and relatives: Each referral to Mikra earns additional entries into the giveaway, encouraging participants to spread the word about Mikra's innovative health and wellness solutions. At the end of the campaign one lucky winner will receive a grand prize of a one-year supply of Mikra products along with exclusive Mikra branded gear. The campaign's goal is to foster deeper engagement with Mikra's loyal customer base while expanding its reach to new audiences during the holiday season.

08:26 EST Greenwave Technology awarded contract valued at $15M-$35M with Core Tree Care - Greenwave Technology is on track to generate $15M-$35M in revenue through a contract with Core Tree Care, related to a prime contract with the Army Corps of Engineers. This high-value contract highlights Greenwave's ability to secure strategic partnerships in critical infrastructure recovery efforts.

08:24 EST Atossa Therapeutics presents data from research investigating Z-Endoxifen - Atossa Therapeutics announced the presentation of research investigating the anti-cancer activity of (Z)-endoxifen and its byproducts at the American Association for Cancer Research, AACR, Special Conference in Cancer Research, taking place in Toronto from December 9-11. The poster, titled, "Anti-cancer activity of (Z)-endoxifen-related compounds in ERalpha+ breast cancer," outlines results from a study investigating four (Z)-endoxifen byproducts for their anti-estrogenic and anti-tumor effects in estrogen receptor-positive breast cancer cell lines, including those with ESR1 mutations associated with endocrine resistance. Notably, compounds AT416E and AT402E demonstrated strong anti-proliferative activity, with AT416E also showing enhanced inhibition of cell migration and invasion. All four byproducts exhibited greater anti-proliferative effects than (Z)-endoxifen in estrogen-deficient conditions, while (Z)-endoxifen remained the most potent at inducing cell cycle arrest and apoptosis, reinforcing its potential as a therapeutic agent.

08:22 EST Clarus' Rhino-Rack acquires certain assets of RockyMounts, terms not disclosed - Clarus announced that Rhino-Rack, a brand in Clarus's Adventure segment, has acquired certain assets of RockyMounts, a Colorado-based brand specializing in bicycle transport products. For over 30 years, RockyMounts has designed innovative roof and hitch rack solutions, attracting a dedicated following of customers thanks to the products' distinct style and exceptional durability. Founded by Bobby Noyes in Boulder, Colorado in 1993, RockyMounts is known for making well designed and dependable premium bicycle racks and other accessories compatible with vehicles of all sizes, including SUVs, vans and trucks. Its award-winning products can be found in local and national retailers across North America. The terms of the transaction were not disclosed, and it was funded using cash on hand.

08:22 EST Critical Metals conirms high-grade rare earth material at its Tanbreez Project - Critical Metals provided a project update for the Tanbreez Greenland Rare Earth Mine, one of the world's largest rare earth assets located in Southern Greenland. "The Tanbreez Project continues to demonstrate its immense upside potential, as the Critical Metals Corp team advances our pre-production plans for this foundational rare earth asset," said Tony Sage, CEO and Executive Chairman of Critical Metals Corp. "On the heels of China's recent decision to restrict the exports of certain rare earth materials, Critical Metals Corp is poised to support western countries with materials essential for producing clean energy applications and supporting their defense industries. Earlier this year, we discovered that the Tanbreez Project contains one of the world's highest concentration of Gallium, and these new results continue to showcase how the asset possesses high-grade rare earth material."

08:21 EST Myriad announces its Prolaris test is still classified as 'Advanced Tool' - Myriad Genetics announced that its Prolaris prostate cancer prognostic test continues to be classified by the National Comprehensive Cancer Network, NCCN, as an 'Advanced Tool' in the fight against prostate cancer. Like other gene expression-based tests, Prolaris for many years has been included in NCCN guidelines with category 2A level of evidence, meaning its inclusion has support from at least 85% of members on the NCCN prostate panel. "The updated NCCN Prostate Cancer Guidelines continue to solidify Prolaris' market position," said Paul J. Diaz, President and CEO, Myriad Genetics. "While there have been certain mischaracterizations regarding the updated guidelines leading to confusion, extensive published evidence shows that Prolaris is a clinically recognized and effective tool in managing patients with prostate cancer. We are confident that our highly engaged clinicians will continue to see the guidelines as an additional reason to incorporate Prolaris in treatment decisions."

08:19 EST Syntec Optics secures $2.1M in new orders for space optics - Syntec Optics announced that it has secured over $2.1 million in orders for its ultra-high-precision space optics. The company will utilize its dedicated production cell to continue delivering products. "Continued orders demonstrate the sustained demand for our advanced optics solutions in the Low Earth Orbit satellite market," said Syntec Optics CFO Dean Rudy. "Our continued commitment to vertical integration, including in-house preform production, allows us to meet the demanding requirements of monthly satellite launches."

08:18 EST SaverOne 2014 launches new pilot project in Italy with Trans Italia - SaverOne 2014 announce the launch of a new pilot project with Trans Italia, a prominent Italian logistics and transportation company well known for its eco-friendly, efficient, and intermodal transport solutions throughout Italy and beyond. "This pilot project with Trans Italia demonstrates our increase in traction within Italy," said Ori Gilboa, CEO of SaverOne. "We are thrilled to collaborate with a forward-thinking company like Trans Italia to demonstrate the value of our technology in improving the safety of their fleet and reducing distracted driving amongst their drivers. We believe this pilot will pave the way for increased adoption of our solutions within Italy and across Europe."

08:17 EST Osisko Gold announces renewal of normal course issuer bid - Osisko Gold Royalties announced that the Toronto Stock Exchange has approved the Corporation's notice of intention to make a normal course issuer bid. Under the terms of the NCIB Program, Osisko may acquire up to 9,331,275 of its common shares from time to time in accordance with the normal course issuer bid procedures of the TSX. The NCIB Program will be conducted through the facilities of the TSX or through alternative trading systems in Canada, if eligible, and will conform to their regulations. Purchases under the NCIB Program will be made by means of open market transactions or such other means as a securities regulatory authority may permit, including pre-arranged crosses, exempt offers and private agreements under an issuer bid exemption order issued by a securities regulatory authority. Repurchases under the NCIB Program may commence on December 12, 2024 and will terminate on December 11, 2025 or on such earlier date as the NCIB Program is completed. Daily purchases will be limited to 73,283 Common Shares, other than block purchase exemptions, representing 25% of the average daily trading volume of the Common Shares on the TSX for the six-month period ending November 30, 2024, being 293,134 Common Shares.

08:16 EST Worksport debuts products on 'Fox & Friends Weekend' - Worksport provided a post-broadcast update following Worksport's appearance on FOX & Friends Weekend, hosted by Will Cain, Rachel Campos-Duffy, and Charlie Hurt. During the nationally televised segment, Worksport's CEO, Steven Rossi, spotlighted the Company's forthcoming mobile power generation system and American-made tonneau covers, underscoring its commitment to innovation, domestic manufacturing, and sustainable solutions. "Our recent feature on FOX & Friends Weekend served as a remarkable springboard, allowing us to debut our COR & SOLIS product to a national audience," said Steven Rossi, CEO of Worksport Ltd. "We received highly positive feedback from the producers and look forward to securing additional national media opportunities as we continue to build brand credibility and expand our market reach. With the support of renowned host Charlie Hurt, we showcased our brand's unique innovations on the channel's 'Made in America' segment. This appearance reaffirmed our commitment to American manufacturing and underscored the transformative potential of our next-generation products. As we move toward 2025, our strategies-ranging from ramped-up U.S. production to cutting-edge solar and portable power technologies-are expected to drive significant revenue growth, improve margins, and enhance shareholder value."

08:14 EST Senseonics provides update on Eversense 365 launch - Senseonics provided commercial updates related to the Eversense 365 launch. "2024 has been a landmark year for Senseonics, achieving our long-term goal of commercializing the Eversense 365 product, providing people with diabetes a convenient and accurate solution for monitoring blood glucose for an entire year with a single sensor," said Tim Goodnow, PhD, President and Chief Executive Officer of Senseonics. "We are excited to see the strong early performance indicators that we believe reflect the commercial potential of this ground-breaking product. Patient and provider leads and new interest from health systems have all increased significantly following 365 launch, and we expect that a heightened level of interest will drive our results for 2025. We intend to provide updates on the ongoing 365 launch, as well as on our product portfolio development, pump-connectivity, additional health care systems, and our ex-US commercial launch of Eversense 365 over the course of 2025."

08:14 EST Bionomics publishes resuls from Phase 2 ATTUNE study of BNC210 - Bionomics announced that the results from its Phase 2 ATTUNE study have been published in the NEJM Evidence. The data were also presented yesterday at the 63 Annual Meeting of the American College of Neuropsychopharmacology as part of the inaugural "Promising Targets" session. Key results from the publication include: Clinician-Administered PTSD Scale for DSM-5 total score improvement was observed with BNC210 compared with placebo at Week 12 with improvement seen as early as Week 4. Clinically meaningful and statistically significant improvements were also observed with BNC210 vs placebo in: Depressive symptoms measured on the Montgomery-Asberg Depression Rating Scale. Sleep measured on the Insomnia Severity Index. Treatment-emergent adverse events occurred in 70 patients in the BNC210 group and 56 in the placebo group. The most common AEs were headache, nausea, fatigue, and hepatic enzyme elevations. The Company is planning to initiate the Phase 3 trial in PTSD in the second half of 2025. BNC210 is also being evaluated in a Phase 3 AFIRM-1 study in social anxiety disorder with anticipated readout in Q3 2025.

08:11 EST Enphase Energy collaborates with NextEnergy in the Netherlands - Enphase Energy announced a collaboration with NextEnergy. This strategic relationship will enable NextEnergy customers with Enphase solar and battery systems to participate in the grid imbalance energy marketplace in the Netherlands, which can help maximize their return on investment and reduce the system payback period.

08:11 EST Dayforce announces two major milestones in Dayforce experience - Dayforce announced two major milestones in the Dayforce on-demand pay experience. Dayforce Wallet has delivered over $5 billion USD through on-demand pay, early direct deposit, and paycard to employees. This achievement highlights the platform's growing adoption and its critical role in providing employees with greater financial flexibility. Additionally, Dayforce is expanding on-demand pay with new direct to bank capabilities, enabling employees to route their pay directly to any personal bank account simply and securely.

08:10 EST Elevai Labs subsidiary announces FDA regulatory pathway for EL-22 - Elevai Labs, subsidiary Elevai Biosciences, announced the next steps in its regulatory strategy for EL-22, aimed at treating obesity and preserving muscle mass. In collaboration with KCRN Research, the Company is preparing for a pre-IND meeting with the FDA, anticipated in the first quarter of 2025. This meeting will establish the development pathway for EL-22, clarifying any additional preclinical requirements and adjustments to Chemistry, Manufacturing, and Controls before IND submission.

08:09 EST Windtree Therapeutics announces new istaroxime patent filing - Windtree Therapeutics announced that it has filed a new istaroxime PCT patent application entitled, "ISTAROXIME DERIVATIVES THEREOF FOR PREVENTING OR REDUCING THE RISK OF ACUTE MYOCARDIAL ARRHYTHMIA." The patent filing expands upon data obtained from animal model testing and the istaroxime human clinical trials in acute heart failure and early cardiogenic shock, including the latest positive Phase 2b istaroxime study in ECS patients. Istaroxime has also shown beneficial effects in rat studies with ischemia-reperfusion induced arrhythmias. Istaroxime-metabolite derivatives have shown superior properties in these models indicating their potential as promising therapeutics for the treatment of patients with ischemia needing improvement in cardiac function.

08:08 EST Artivion: FDA grants HDE for use of AMDS Hybrid Prosthesis - Artivion announced that the U.S. FDA has granted a Humanitarian Device Exemption for use of the AMDS Hybrid Prosthesis in acute DeBakey Type I dissections in the presence of malperfusion. The AMDS is the world's first aortic arch remodeling device for use in the treatment of acute DeBakey Type I aortic dissections.

08:07 EST Genius Group increased its Bitcoin purchases for its Treasury by $2.2M - Genius Group announced that it had increased its Bitcoin purchases for its Bitcoin Treasury by an additional $2.2 million to 191 Bitcoin for $18 million, at an average price of $92,728 per Bitcoin. The Company's announced on November 12 of its "Bitcoin-first" strategy that it is committing 90% or more of its current and future reserves to be held in Bitcoin, with an initial target of $120 million in Bitcoin. Following its initial purchase of $10 million in Bitcoin in the week of the announcement, in the four subsequent weeks it has been adding an average of $2 million per week to its Bitcoin reserve.

08:06 EST Crinetics announces FDA acceptance of NDA for paltusotine - Crinetics Pharmaceuticals announced the U.S. Food and Drug Administration, FDA, accepted its New Drug Application, NDA, for investigational candidate paltusotine for the treatment and long-term maintenance therapy of acromegaly in adults. If approved, paltusotine will be the first and only once-daily, oral, selective somatostatin receptor type 2 nonpeptide agonist available for adults living with acromegaly. "With our patient-centered clinical development of paltusotine, we were guided by an unwavering ambition to deliver a new generation of treatment that provides a once-daily, oral alternative to the currently marketed peptide analog drugs," said Scott Struthers, Ph.D., Founder and Chief Executive Officer of Crinetics. "We look forward to working with the FDA throughout the review of our new drug application, as we also prepare for a potential commercial launch by building out our infrastructure and engaging with payers and the endocrinology community."

08:06 EST Harmonic, Sercomm announce strategic collaboration on DOCSIS 4.0 - Sercomm and Harmonic announced an exclusive technology collaboration to advance DOCSIS 4.0 unified technologies. As part of this partnership, Sercomm will introduce its new DOCSIS 4.0 Unified Amplifiers, benefiting from Harmonic's expertise in FDX and unified nodes. The collaboration between Sercomm and Harmonic will not only enable symmetrical upstream and downstream data speeds but also improve interoperability between network components, reducing integration complexities for service providers. This seamless interoperability allows operators to maximize their existing infrastructure as they transition to DOCSIS 4.0, ensuring faster, more reliable deployments with minimized risks.

08:04 EST Novolex to acquire Pactiv Evergreen for $18.00 per share in cash - Novolex and Pactiv Evergreen have entered into a definitive agreement to combine, creating a leading manufacturer in food, beverage and specialty packaging products. The combination brings together two highly complementary businesses that will offer a broad product platform, establishing one of the most diverse substrate offerings in the packaging industry. The asset base will include an extensive manufacturing footprint and an expansive distribution network, enhancing the combined company's ability to serve customers ranging from large, blue-chip brands to small businesses that serve millions of consumers every day. Under the terms of the agreement, Novolex will acquire Pactiv Evergreen for $18.00 per share in an all-cash transaction valued at $6.7 billion, inclusive of Pactiv Evergreen's net debt as of September 30, 2024. The transaction consideration represents a 49% premium to the two-month unaffected volume weighted average trading price as of December 2, 2024, the last trading day prior to media reports regarding a potential transaction. Upon the completion of the transaction, Pactiv Evergreen will become a privately held company, and its common stock will no longer be listed on Nasdaq. The combined company will be led by Novolex Chairman and CEO Stan Bikulege. This transaction is supported by funds managed by affiliates of Apollo (APO), the majority shareholder of Novolex since 2022, and Canada Pension Plan Investment Board, which will contribute approximately $1 billion and will become a significant minority shareholder in the post-merger company. The transaction has been approved by the Pactiv Evergreen Board of Directors and is subject to receipt of regulatory approvals and other customary closing conditions. The transaction has also been approved by Packaging Finance Limited, in its capacity as the majority shareholder of Pactiv Evergreen, and no other shareholder approval is required. The transaction is not subject to a financing condition and is expected to close in mid-2025.

08:02 EST Clarus appoints Mark Besca to board of directors - Clarus announced that the Company's Board of Directors appointed Mr. Mark Besca to serve on the Board, effective as of December 5, 2024. With Mr. Besca's appointment, the Board will be comprised of seven directors, six of whom are independent. Mr. Besca was also appointed to the Audit Committee of the Company's Board. Since 2020, Mr. Besca has been a member of the board of directors and Audit Committee Chair of Markel Group Inc., a New York Stock Exchange listed financial holding company with diverse operations. Prior to his retirement in 2020, he spent 40 years at EY serving as lead and senior advisory audit partner to some of the largest public companies in the media and entertainment, consumer products and airline industries.

07:56 EST Koppers Holdings announces retirement of two senior leaders - Koppers Holdings announced the retirement of two senior leaders who, respectively, established sustainability and safety as central priorities of the company. Leslie Hyde, Senior Vice President and Chief Sustainability Officer, will retire effective March 31, 2025, and Joseph Dowd, Global Vice President Zero Harm, will retire effective February 28, 2025. Effective immediately, both will serve as Assistant to the CEO in order to help ensure a smooth transition.

07:49 EST LeddarTech enters into amendments to credit facility, bridge financing - LeddarTech Holdings (LDTC) announced that LeddarTech and Texas Instruments (TXN) have entered into a strategic collaboration agreement and a software license agreement to enable a comprehensive, integrated platform solution for advanced driver assistance systems and autonomous driving markets. Under the license agreement, TI has agreed to make advanced royalty payments to catalyze joint commercialization. In connection with the collaboration and license agreements with TI and the advanced royalty payments provided thereunder, LeddarTech entered into: a fourteenth amending agreement with Federation des caisses Desjardins du Quebec with respect to the amended and restated financing offer dated as of April 5, 2023, pursuant to which Desjardins has agreed to, among other things: temporarily postpone payment of interest for the months of July through December 2024 until the earlier of the date of the final disbursement of one or several equity investments in the borrower for minimum gross proceeds amount of $35,000,000 in the aggregate, and January 31, 2025 assuming the disbursement to LeddarTech of the full first installment of the TI Pre-paid Royalty Fee; and temporarily suspend the minimum cash covenant under the Desjardins Credit Facility until the earlier of December 13, 2024, and the date of disbursement to LeddarTech of the full first installment of the TI Pre-paid Royalty Fee, after which time LeddarTech will be required to maintain a minimum cash balance of C$1,000,000 until the earlier of the Short-Term Outside Date, and January 31, 2025, and a minimum cash balance of C$5,000,000 at all times after such date. a second amending agreement with the initial bridge lenders and certain members of management and the board of directors with respect to the bridge financing offer dated as of August 16, 2024 pursuant to which the Bridge Lenders have agreed, among other things, to extend the maturity of the bridge loan to December 13, 2024, which date will automatically be extended upon the disbursement by TI to LeddarTech of the full first installment of the TI Pre-paid Royalty Fee, to the earlier of January 31, 2025 and the business day following the Short-Term Outside Date. The Fourteenth Amending Agreement to the Desjardins Credit Facility also provides for a monthly payment by LeddarTech to Desjardins of C$125,000 until the Short-Term Outside Date, which payments will be due and payable on the earlier of the Short-Term Outside Date and December 13, 2024, provided that if the full first installment of the TI Pre-paid Royalty Fee is received on or before December 13, 2024, the deferral will extend to the earlier of the Short-Term Outside Date, and January 31, 2025.

07:44 EST Silence Therapeutics announces additional results from SANRECO study - Silence Therapeutics announced additional results from the Phase 1 open label portion of the SANRECO study of divesiran, a siRNA targeting TMPRSS6, in patients with polycythemia vera were presented at the American Society of Hematology annual Mmeeting being held in San Diego, California. Initial results from the SANRECO Phase 1 study were presented in June and showed that all doses of divesiran substantially reduced phlebotomy frequency and lowered hematocrit in 16 phlebotomy dependent PV patients regardless of baseline HCT levels. Additional data presented at ASH further support those findings and included 19 PV patients with a combined history of 79 phlebotomies prior to enrolment. Following divesiran dosing, only five phlebotomies occurred during the 18-week treatment period - all were in patients who entered the study with high baseline HCT levels. Two phlebotomies occurred in the 16-week follow-up period following the last administered dose. Consistent with results reported in June, there was a sustained reduction in HCT during the treatment period and favorable effects on indices of iron metabolism. Hepcidin levels increased and were sustained within physiological levels in all dose groups, demonstrating consistent target engagement. Importantly, divesiran continues to be well tolerated to-date with no dose-limiting toxicities.

07:42 EST Hive Digital announces 103 bitcoin produced in November - HIVE Digital Technologies has released its unaudited production results for November 2024. Bitcoin Production: HIVE mined 103 BTC, bringing its HODL portfolio to 2,713 BTC, a 67% increase year-over-year. Mining Capacity: Maintained an average mining capacity of 5.3 Exahash per Second with fleet efficiency at 22.3 Joules per Terahash, reaching a peak hashrate of 5.7 EH/s. Operational Efficiency: Achieved an average daily production rate of 3.42 BTC, equivalent to 19.3 Bitcoin per Exahash. Bitcoin Valuation: HIVE's Bitcoin holdings were valued at over $261 million as of November 30, 2024, based on a BTC closing price of approximately $96,400.

07:42 EST Independent Bank, Enterprise Bancorp sign $562M merger agreement - Independent Bank (INDB) and Enterprise Bancorp (EBTC) have signed a definitive merger agreement pursuant to which Enterprise will merge into Independent and Enterprise Bank will merge into Rockland Trust in a cash and stock transaction for total consideration valued at approximately $562M in aggregate, or $45.06 per share based on the Independent closing price of $71.77 on December 6. The merger agreement provides that Enterprise shareholders will receive 0.60 shares of Independent common stock and $2.00 in cash for each share of Enterprise common stock they hold. The transaction is intended to qualify as a tax-free reorganization for federal income tax purposes and to provide a tax-free exchange for Enterprise shareholders for the Independent common stock portion of the merger consideration they will receive. Independent anticipates issuing approximately 7.5M shares of its common stock and paying an aggregate amount of $27.1M in cash in the merger. The merger is expected to close in the second half of 2025 subject to customary closing conditions, including regulatory approvals and approval of Enterprise shareholders. No vote of Independent shareholders is required. The merger is expected to be approximately 16% accretive to Independent's earnings per share in 2026, the first full year of combined operations, assuming full phase-in of cost savings. Independent anticipates the transaction will meet its three year or less tangible book value earn back hurdle rate. Combined merger-related charges are expected to be approximately $61.2M before tax, in the aggregate. As part of the transaction, Independent plans to raise approximately $250M in subordinated debt prior to the transaction closing. Post close, board chair and Enterprise Bank founding member, George Duncan, will become an advisor to the independent board and Larochelle will serve as a consultant for Rockland Trust for one year. Additionally, Independent will appoint two Enterprise directors to its board following the merger. The boards of directors of each company have unanimously approved the transaction. Enterprise's directors and executive officers who currently own, in the aggregate, about 20.4% of Enterprise's outstanding shares have signed voting agreements pursuant to which they have agreed to vote their shares in favor of the merger.

07:41 EST Idexx Laboratories announces 5M share increase in share repurchase pact - IDEXX Laboratories announced that the Company's Board of Directors authorized an increase in its ongoing share repurchase program, authorizing the repurchase of up to five million additional shares of the Company's common stock. Repurchases may be made at management's discretion from time to time in the open market or in negotiated transactions. These shares are in addition to the 1.3 M shares remaining under the Company's ongoing share repurchase program as of December 3 pursuant to previous Board authorizations. The share repurchase program has no specified expiration date and may be suspended or discontinued at any time.

07:39 EST Stereotaxis, Medtech announce catheter approved by China's NMPA - Stereotaxis and Shanghai MicroPort EP Medtech announced that the Magbot Magnetic Navigation Ablation Catheter has received regulatory approval from China's National Medical Products Administration, NMPA. The Magbot Catheter is a single-use magnetic saline-irrigated radiofrequency ablation catheter designed and developed by MicroPort EP in collaboration with Stereotaxis. The catheter works exclusively and in tight conjunction with Stereotaxis' robotic systems, including the recently NMPA-approved Genesis RMN, and MicroPort EP's Columbus 3D EP Mapping System.

07:38 EST Bowman selected to lead engineering on 64 MW solar system, no terms - Bowman Consulting Group announced that it has been selected by J. Ranck Electric or JRE to lead the re-mobilization of a 64 MW direct current DC solar project located in Southeast Michigan. This expansion will enhance the substations capabilities to support additional solar power generation, integrating new photovoltaic PV capacity alongside existing wind power infrastructure. Under this contract, Bowman will perform a comprehensive suite of services, including electrical engineering, civil design and system modeling to support the integration of JREs solar power installation into the US power grid....This project marks significant steps forward both in our energy services practice and in our partnership with J. Ranck Electric, said Dan Swayze, chief operating officer of Bowman. We are excited to deploy our energy engineering and design capabilities to help JRE enhance Michigans renewable energy capacity and grid stability. This assignment reinforces our commitment to delivering diversification and organic growth as we continue to expand our renewables and traditional energy portfolio nationally.

07:38 EST Aterian announces launch of three new products - Aterian announced the launch of three new products, now available for purchase on Amazon.com and Walmart.com. These products will also be available on MercadoLibre and Target+ by next week. The product launches include two additions to Aterian's PurSteam brand and one to its Mueller Living brand. The newly launched PurSteam products, the Steam Station Max and the ScrubMaster showcase the brand's commitment to innovation, quality, and meeting the evolving needs of its customers. The Cordless Portable Vacuum Sealer is the latest addition to Mueller Living's lineup of innovative, practical, and affordable kitchen solutions.

07:37 EST AST SpaceMobile announces commercial agreement with Vodafone through 2034 - AST SpaceMobile (ASTS) and Vodafone (VOD) announced that they have entered into a definitive long-term commercial agreement through 2034. This is a significant step forward in their collaboration to expand broadband connectivity globally. This agreement establishes the framework for Vodafone to offer space-based cellular broadband connectivity in its home markets, as well as to other operators via its Partner Markets program.

07:36 EST LeddarTech announces collboration agreement with Texas Instruments - LeddarTech (LDTC) announced that LeddarTech and Texas Instruments (TXN) have entered into a strategic collaboration agreement and a software license agreement to enable a comprehensive, integrated platform solution for advanced driver assistance systems, ADAS, and autonomous driving, AD, markets. Under the license agreement, TI has agreed to make advanced royalty payments to catalyze joint commercialization. The collaboration and license agreements will enable TI to market a bundled solution that features LeddarTech's LeddarVision AI-based fusion and perception software stack pre-integrated and validated on TI's TDA scalable portfolio of Arm-based processors. LeddarTech and TI have worked closely for nearly two years to integrate LeddarTech's software with TI's hardware to create an open, comprehensive, high-performance and cost-efficient solution for ADAS and AD systems that can serve the entire automotive OEM landscape and their Tier 1 suppliers.

07:35 EST Syndax announces additional positive data from AUGMENT-101 trial of Revuforj - Syndax Pharmaceuticals announced additional positive data from the AUGMENT-101 trial of Revuforj in relapsed or refractory mutant NPM1 acute myeloid leukemia and the BEAT AML trial of revumenib in combination with venetoclax and azacitidine in newly diagnosed AML patients. Revuforj is the company's oral, first-in-class menin inhibitor that is FDA approved for the treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene translocation in adult and pediatric patients one year and older. Syndax announced today additional results from the Phase 2 cohort of R/R mNPM1 AML patients in the AUGMENT-101 trial, including data generated from the protocol-defined efficacy population of 64 adults and a post-hoc efficacy analysis based on all patients who met the efficacy evaluable criteria. Subgroup analyses from the Phase 2 protocol-defined R/R mNPM1 efficacy population (N=64) show that CR/CRh responses were observed across all major subgroups, including patients with multiple prior lines of therapy and prior venetoclax exposure, although the trial was not powered to evaluate differences among subgroups. The CR+CRh rate was 25% (4/16) among patients with 1 prior line of therapy, 20% (5/25) among patients with 2 prior lines of therapy, and 26% (6/23) among patients who had received three or more prior lines of therapy. The CR+CRh rate was 44% (7/16) among patients without prior venetoclax exposure and 17% (8/48) among patients with prior venetoclax exposure. Historically, AML patients who have failed prior treatment with venetoclax are unlikely to respond to subsequent therapy, with a CR rate of 6% reported for other targeted therapies after prior venetoclax therapy.2 Syndax also shared results from an expanded analysis of the R/R mNPM1 AML patients who enrolled into the Phase 2 cohort of AUGMENT-101. Among the 84 patients enrolled in the cohort, 77 met the efficacy evaluable criteria requiring patients to have blast counts greater than5% measured within 28 days prior to treatment and a centrally confirmed NPM1 mutation. In this expanded post-hoc efficacy analysis, 48% (37/77; 95% CI: 37%, 60%) achieved an overall response, and 26% (20/77; 95% CI: 17%, 37%) achieved a CR/CRh. The median duration of CR/CRh response was 4.7 months as of the September 2024 DCO. Minimal residual disease status was assessed in 19 of 20 patients who achieved CR/CRh, 63% (12/19) of whom were MRD negative.

07:34 EST Repligen launches AVIPure dsRNA Clear OPUS columns - Repligen announced the launch of AVIPure dsRNA Clear OPUS columns, a solution designed to simplify and enhance the production of mRNA therapeutics and vaccines. This novel affinity chromatography offering marries Repligen's breakthrough dsRNA purification resin with its flagship OPUS pre-packed columns. The AVIPure dsRNA Clear resin offers unmatched performance in the removal of double-stranded RNA impurities from transcribed RNA. As the market for mRNA-based biologics has expanded, so has the critical need for better dsRNA removal, to enable the highest levels of drug efficacy in patients, while reducing or preventing any undesirable immune responses. The AVIPure dsRNA Clear OPUS columns directly address this need, with a convenient, closed system for mRNA manufacturers. The AVIPure dsRNA Clear resin launch follows last week's formal completion by Repligen of its acquisition of Tantti Laboratory Inc., announced on July 29, 2024. The AVIPure dsRNA Clear resin product combines our proprietary affinity ligands with Tantti's DuloCore base bead technology. The result is a 2-3 log reduction of dsRNA impurities in just one minute of residence time in flow through mode. Unlike traditional methods, this advanced solution eliminates the need for heat or solvents, providing an easy-to-use, scalable option for manufacturers, and enabling a highly efficient, cost-effective process that ensures the production of high-purity mRNA therapeutics and vaccines. Designed for flexibility and performance, the resins come pre-packed in OPUS chromatography columns, ensuring seamless integration into biomanufacturing workflows.

07:32 EST Omnicom to acquire Interpublic Group in a stock-for-stock transaction - Omnicom (OMC) and The Interpublic Group of Companies (IPG) announced their Boards of Directors have unanimously approved a definitive agreement pursuant to which Omnicom will acquire Interpublic in a stock-for-stock transaction. Under the terms of the agreement, Interpublic shareholders will receive 0.344 Omnicom shares for each share of Interpublic common stock they own. Following the close of the transaction, Omnicom shareholders will own 60.6% of the combined company and Interpublic shareholders will own 39.4%, on a fully diluted basis. The transaction is expected to generate annual cost synergies of $750M. John Wren will remain Chairman & CEO of Omnicom. Phil Angelastro will remain EVP & CFO of Omnicom. Philippe Krakowsky and Daryl Simm will serve as Co-Presidents and COOs of Omnicom. Krakowsky will also be Co-Chair of the Integration Committee post-merger. Three current members of the Interpublic Board of Directors, including Philippe Krakowsky, will be welcomed to the Omnicom Board of Directors. The stock-for-stock transaction is expected to be tax-free to both Omnicom and Interpublic shareholders and is expected to close in the second half of 2025, subject to Omnicom and Interpublic shareholder approvals, required regulatory approvals, and other customary conditions. The combined company will retain the Omnicom name and trade under the "OMC" ticker symbol on the New York Stock Exchange.

07:32 EST Vor Bio announces updated data from Phase 1/2 VBP1-1 study - Vor Bio announced updated clinical data from its ongoing Phase 1/2 VBP101 study of patients with relapsed/refractory AML receiving trem-cel followed by Mylotarg. The data, which was presented in a poster at the American Society of Hematology (ASH) Annual Meeting on Sunday, December 8th, demonstrated durable engraftment, shielding from Mylotarg on-target toxicity, a broadened Mylotarg therapeutic window, and early evidence of improved relapse free survival compared to published high-risk AML comparators. The data released today included 25 patients treated with trem-cel of which 15 had received Mylotarg as of the data cut-off date of November 1, 2024. The data demonstrated: Preliminary evidence of improved relapse-free survival compared to published groups of AML patients at high risk of relapse post hematopoietic stem cell transplant. Shielding of the blood system, with maintained neutrophil and platelet counts across multiple Mylotarg doses of 0.5, 1, and 2 mg/m2. Broadened therapeutic index for Mylotarg when administered after trem-cel. Reliable engraftment, with 100% of patients achieving primary neutrophil engraftment, robust platelet recovery, and full myeloid donor chimerism at Day 28. Trem-cel continues to be manufactured with high CD33 editing efficiency

07:30 EST Omnicom to acquire Interpublic Group in a stock-for-stock transaction

07:16 EST Focus Universal to debut Universal Smart Device, Universal IoT Platform at CES - Focus Universal announced that it will debut its universal smart devices and universal smart IoT platform in booth 9877 in the North Hall Showcase of the Las Vegas Convention Center, January 7-10, 2025. The company's universal smart device, Ubiquitor, is a solution capable of connecting to any sensor or a vast number of independent sensors, theoretically without limit. When a moderate number of sensors are connected, the cost of the Ubiquitor, averaged across sensors, becomes negligible. The effective cost approaches that of the sensors alone, which represents just a fraction of the material costs of traditional devices. Additionally, the Ubiquitor's efficiency and cost-effectiveness are evident when coupled with Focus' platform system, whereby development costs are a fraction of traditional device development requirements, resulting in substantial savings in both raw material and development costs. The universal smart platform to building IoT infrastructure eliminates redundancy in IoT hardware and software design. Instead of starting from scratch, engineers can begin their IoT projects with a foundation which is 90% complete. This approach allows different IoT devices to share 90% of the same hardware and software, significantly lowering costs and simplifying design processes.

07:10 EST NFI Group subsidiary MCI announces new contract with Houston METRO - NFI Group subsidiary Motor Coach Industries, MCI, announced a new contract with Metro Transit Authority of Harris County, METRO, for the purchase of 100 MCI D45 CRT high-floor coaches. The initial purchase for the contract included 50 firm coaches and 50 options, which were added to MCI's Q3 2024 firm and option awards. METRO exercised the option for 50 more coaches in November bringing the total firm quantity to 100 coaches.

07:09 EST InspireMD announces first patient enrolled in CGUARDIANS II study - InspireMD announced that the first patient has been enrolled in the company's CGUARDIANS II clinical trial evaluating its CGuard Prime Carotid Stent System in patients undergoing carotid artery stenting via the Transcarotid Artery Revascularization approach. The patient was enrolled by Dr. Patrick Muck at Good Samaritan Hospital, part of the TriHealth System in Cincinnati, Ohio. Dr. Muck serves as both the site principal investigator as well as a co-lead investigator of the CGUARDIANS II study.

07:08 EST Seres Therapeutics granted Breakthrough Therapy designation for SER-155 - Seres Therapeutics announced that the US Food and Drug Administration has granted Breakthrough Therapy designation to SER-155, the Company's lead investigational program, for the reduction of bloodstream infections in adults undergoing allogeneic hematopoietic stem cell transplant for the treatment of hematological malignancies. In September 2024, Seres reported topline clinical data from Cohort 2 of its SER-155 Phase 1b placebo-controlled study in patients undergoing allo-HSCT, in which SER-155 was associated with a significant reduction in BSIs, a significant reduction in systemic antibiotic exposure, and lower incidence of febrile neutropenia, in each case as compared to placebo, through day 100 post-HSCT. Additionally, SER-155 was generally well tolerated, with no observed treatment-related serious adverse events. The receipt of Breakthrough Therapy designation for SER-155, the Company's second program to receive such designation, grants Seres access to FDA senior management and a commitment from FDA to work closely with the Company, facilitating an efficient drug development process. In December 2023, SER-155 received FDA Fast Track designation for reducing the risk of infection and GvHD in this patient population. The SER-155 Breakthrough Therapy designation was supported by positive data from our recent SER-155 Phase 1b clinical trial. Patients who received SER-155 experienced a significantly lower incidence of bacterial BSIs as compared with the placebo arm, representing a 77% relative risk reduction. In addition, while antibiotic starts were similar in each arm, patients administered SER-155 were treated with antibiotics for a significantly shorter duration compared to patients in the placebo arm. Further, the incidence of febrile neutropenia was reduced, and gastrointestinal pathogen domination was substantially lower compared to a historical control cohort, providing further evidence of SER-155's activity in modulating the microbiome to address critical post-transplant complications. SER-155 was well tolerated with no treatment related serious adverse events and engrafted as expected in the gastrointestinal tract. Bloodstream infections in allo-HSCT patients are frequent, serious, and potentially fatal. In clinical practice, HSCT patients who experience a BSI or febrile neutropenia are aggressively treated, often with broad-spectrum antibiotics, as infections are a leading cause of death in these patients in the first 100 days post-transplant. While prophylaxis of BSIs with antibiotics is common, antibiotics do not address the root cause as SER-155 is designed to do. Recent market research conducted by Seres characterized a significant commercial opportunity for SER-155 in allo-HSCT. Health Care Providers treating allo-HSCT patients indicated a high level of concern regarding BSIs. Additionally, HCPs stated that they would rapidly add a product providing similar efficacy to what we have observed in our SER-155 study to standard treatment protocols. The approximately 40,000 worldwide allo-HSCT patients are treated in a subset of large oncology centers across the globe, enabling rapid and efficient education of HCPs about SER-155, if approved. In addition to allo-HSCT, bloodstream infections are a common and serious complication in many other medically vulnerable populations, including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities. Seres intends to explore development of SER-155 and additional pipeline candidates for these populations. The targeted patient populations for SER-155 and Seres' other pipeline candidates could represent multiple blockbuster commercial opportunities. Seres is actively seeking a partner to provide financial resources and other capabilities to support the Company's goal to maximize the SER-155 program opportunity, while pursuing a capital-efficient development approach.

07:06 EST Cemtrex awarded two projects totaling $6.7M through its AIS subsidiary - Cemtrex announced it has been awarded two project contracts totaling $6.7 million through its Advanced Industrial Services, AIS, subsidiary. The contracts are for upgrades at the Clearwater Road Wastewater Treatment Facility in Derry Township, Pennsylvania, managed through the Derry Township Municipal Authority, DTMA. The Clearwater Road Wastewater Treatment Facility, operational since 1977, has a treatment capacity of 5.02 million gallons per day. The AIS contracts encompass a general contract and HVAC contract for the addition of a new owner-supplied gasification-drying process and ancillary processes to support the new gasification-drying process. This process is integral to the facility's innovative biosolids management program, which converts residual solids from wastewater into an exceptional quality granular fertilizer. The project is expected to be completed by the calendar year end of 2025.

07:05 EST Coherent signs PMT with U.S. Department of Commerce under CHIPS act - On Friday, December 5, 2024, it was announced that Coherent has signed a non-binding preliminary memorandum of terms, PMT, with the U.S. Department of Commerce under the CHIPS and Science Act for a proposed investment of up to $33 million to support the modernization and expansion of a state-of-the-art manufacturing cleanroom in Coherent's existing 700,000 square-foot facility in Sherman, Texas. This project will expand the world's first 150 mm indium phosphide manufacturing line by adding advanced wafer fabrication equipment to produce InP devices at scale. "This proposed investment allows Coherent to accelerate our industry leadership in InP technology and manufacturing," said Dr. Giovanni Barbarossa, Chief Strategy Officer and President, Materials Segment, for Coherent.

07:04 EST Cogent Biosciences announces updates results from SUMMIT - Cogent Biosciences announced updated clinical results from the Open Label Extension OLE, portion of SUMMIT, a clinical trial evaluating bezuclastinib in patients with nonadvanced systemic mastocytosis. The OLE data are being presented at the 66th American Society of Hematology Annual Meeting & Exposition taking place December 7-10, 2024 in San Diego, CA. Updated clinical data presented today show: 56% mean improvement in Total Symptom Score at 24 weeks; 76% of patients demonstrated greater than50% reduction from baseline in MS2D2 Total Symptom Score with 88% of patients exceeding 30% reduction from baseline after 24 weeks; 49% mean improvement in MC-QoL Total Score at 24 weeks. Bezuclastinib showed rapid, deep, and sustained reductions in serum tryptase over the course of 24 weeks of treatment including: 89% of patients had greater than50% decrease in serum tryptase levels by four weeks of treatment; 95% of patients with baseline tryptase greater than or equal to20ng/mL achieved less than20ng/mL by week 24; 84% of patients with baseline serum tryptase greater than11.4ng/ml achieved less than11.4ng/mL by week 24.

07:03 EST ICE expands global energy offering with launch of Japanese power futures - Intercontinental Exchange announced the latest addition to its global energy offering with the launch of Japanese Power Futures. ICE has launched four Japanese Power Financial Baseload and Peakload Futures covering the Tokyo and Kansai areas respectively, allowing market participants to manage exposure to the day-ahead auction price of the Japanese Electric Power Exchange or JEPX, for these areas. "By offering Japanese Power Futures on a single platform alongside our natural gas, coal, oil, clean energy attributes and carbon contracts, ICE is providing customers with a critical edge in navigating energy markets," said Gordon Bennett, Managing Director of Utility Markets at ICE. "Secondary fuels including electricity are produced through the conversion of primary energy sources like natural gas, coal and oil, and the price of electricity is derived from the interaction of these competing input fuels, all of which trade on ICE. Natural gas and coal make up the majority of Japan's electricity generation and through trading of these contracts on ICE, customers benefit from improved price dissemination." ICE's Japanese Power Financial Futures will be offered in monthly, quarterly and seasonal contracts as well as a Calendar and Fiscal Year contract. In addition, customers can trade spreads between Tokyo and Kansai to manage positions and price differences across these regions, as well as manage exposure to regional price risks.

07:02 EST Lattice Semiconductor announces $100M share repurchase program - Lattice Semiconductor announced that its board of directors authorized the company to repurchase up to an additional $100M of its outstanding common stock through the end of December 2025. The company has repurchased approximately 6M shares since the fourth quarter of 2020 thereby reducing dilution by 4.3%. The 2025 repurchase program is effective immediately.

07:02 EST Next Hydrogen Solutions provides update on working capital debt financing - Next Hydrogen Solutions has received a Letter of Interest from Export Development Canada, for potentially up to $5M in working capital debt financing. EDC's potential financing commitment, structure and terms are contingent upon its satisfactory completion of technical, environmental, social and governance, financial and commercial due diligence. As such, the LOI should not be construed as a financing commitment.

06:57 EST Aecom appointed by Thames Water to new GBP 400M services framework - Aecom announced its appointment by Thames Water to a new professional services framework in the UK. This new GBP 400M framework, FA1980, covers asset, capital and engineering professional services, and brings together a series of separate Thames Water frameworks under a single package. Thames Water is the utility responsible for the water supply and waste-water treatment across much of south-east England, including London and the Thames Valley. This new framework will aid the utility's efforts to improve water and wastewater services, upgrade infrastructure, prevent leakages and pollution, and enhance the environment, as it seeks to deliver its overall 2025-2030 business plan for the UK's Asset Management Plan Period 8 regulatory period.

06:46 EST Merck says Phase 3 KEYLYNK-001 trial met primary endpoint - Merck announced that the Phase 3 KEYLYNK-001 trial evaluating KEYTRUDA plus chemotherapy followed by maintenance with LYNPARZA, with or without bevacizumab, as a first-line treatment for people with BRCA non-mutated advanced epithelial ovarian cancer met its primary endpoint of progression-free survival. At the final analysis conducted by an independent Data Monitoring Committee, the KEYTRUDA plus LYNPARZA regimen demonstrated a statistically significant and clinically meaningful improvement in PFS for these patients compared to chemotherapy alone. The study did not reach its secondary endpoint of overall survival. The role of KEYTRUDA in the intention-to-treat population remains uncertain at this time. The safety profiles of KEYTRUDA and LYNPARZA were consistent with those observed in previously reported studies for the individual therapies. These results will be presented at an upcoming medical meeting and discussed with regulatory authorities.

06:35 EST Protalix, Chiesi announce EMA validation of pegunigalsidase Variation Submission - Chiesi Global Rare Diseases and Protalix announced that the European Medicines Agency, or EMA, has validated the Variation Submission for pegunigalsidase alfa to label a less frequent dosing regimen at a dose of 2 mg/kg body weight administered every four weeks in adult patients with Fabry disease. The currently approved dose of pegunigalsidase alfa is 1 mg/kg administered every two weeks. The variation application is supported by a revised Population-PK model and new exposure-response analyses and by the clinical data on pegunigalsidase alfa 2 mg/kg E4W from the completed Phase 3 study PB-102-F50 and its ongoing extension study CLI-06657AA1-03, that have investigated the 2 mg/kg every four weeks dosing regimen in adult patients with Fabry disease who were previously treated with agalsidase-alfa or -beta administered every two weeks. Results of the completed study PB-102-F50 were recently published in the Journal of Inherited Metabolic Disease.

06:33 EST Parsons wins $53M three-year contract by RCRC in Saudi Arabia - Parsons announced that the company has been awarded a $53M, three-year contract by the Royal Commission for Riyadh City in Saudi Arabia for program management office services on its Main and Ring Roads Program. Under the contract, Parsons will be the PMO for all new major road development programs in Riyadh, providing overall management and control of construction activities. The program includes approximately 500km (about 310 miles) of new and improved road corridor works. Key objectives of the program are to keep the city moving during construction and also to meet the requirements associated with the growth plans for the City of Riyadh, including tackling congestion and hosting global events such as the Expo 2030 and FIFA World Cup 2034. Upon completion, the new road network will reduce hours lost in traffic, leading to improved average trip durations and enhanced connectivity across the city.

06:32 EST VirnetX names John Anthony Jamison CTO - VirnetX announced that it has hired John Anthony Jamison as new VirnetX CTO. Most recently, Jamison was the CTO at an AI/ML start-up, OmniTeq, where he worked to developed commercial services in the fields of bioinformatics, energy and power optimization, and climate related analytics.

06:23 EST Macquarie Asset Management announces partnership with Dow - Macquarie Asset Management announced that a fund managed by Macquarie Asset Management has entered into a definitive agreement to acquire a 40% equity stake in select U.S. Gulf Coast infrastructure assets of Dow Inc. This new partnership, Diamond Infrastructure Solutions, will be a specialist infrastructure provider to Dow and other industrial customers at its five locations in Texas and Louisiana, offering comprehensive services to its tenants with a focus on world class efficiency, reliability and safety. As a dedicated infrastructure company, Diamond will be a new business model with greater strategic focus on operational efficiencies and new customer acquisition. Diamond is comprised of certain non-product producing assets (power and steam production, pipelines, environmental operations and general site infrastructure) located at five of Dow's manufacturing sites in the U.S. Gulf Coast: Freeport, Texas City, and Seadrift in Texas, as well as Plaquemine and St. Charles in Louisiana. Pipeline and storage assets span across the USGC with connections to major natural gas, NGL and olefin hubs. Dow expects to receive initial cash proceeds of approximately $2.4B based on the sale of its 40% minority equity stake with the potential to generate cash proceeds up to approximately $3B for a 49% minority equity stake. Macquarie Asset Management will have the option to increase its equity share to 49% within six months of closing. Dow and Macquarie Asset Management expect to close the transaction in the first half of 2025, subject to customary regulatory approvals and other closing conditions.

06:14 EST Dow Inc. to sell 40% stake in select Gulf Coast infrastructure assets for $2.4B - Dow announced that it has entered into a definitive agreement to sell a 40% equity stake in select U.S. Gulf Coast infrastructure assets to a fund managed by Macquarie Asset Management. This new partnership, Diamond Infrastructure Solutions, will be a specialist infrastructure provider to Dow and other industrial customers at its five locations in Texas and Louisiana, offering comprehensive services to its tenants with a focus on world class efficiency, reliability and safety. As a dedicated infrastructure company, Diamond will be a new business model with greater strategic focus on operational efficiencies and new customer acquisition. Profitable growth for Diamond will benefit both Dow and Macquarie Asset Management's future bottom-line results. Dow expects to receive initial cash proceeds of approximately $2.4B based on the sale of its 40% minority equity stake with the potential to generate cash proceeds up to approximately $3B for a 49% minority equity stake. Macquarie Asset Management will have the option to increase its equity share to 49% within six months of closing. Dow and Macquarie Asset Management expect to close the transaction in the first half of 2025, subject to customary regulatory approvals and other closing conditions.

06:06 EST Jeffs' Brands wins global exclusive for drone system distribution on Amazon - Jeffs' Brands (JFBR), a data-driven e-commerce company operating on the Amazon (AMZN) Marketplace, announced that it has entered into an agreement granting it the exclusive worldwide right to distribute certain advanced drone safety systems developed by a leading drone company for a period of two years and subject to certain conditions. The innovative drone safety systems will be sold by the company exclusively through the Amazon's global marketplace. The entry into the agreement, previously announced, highlights Jeffs' Brands' commitment to leveraging its expertise in e-commerce to bring advanced technological solutions to consumers. With a focus on high standards of reliability and performance, these drone safety systems are set to address key challenges in the industry.

06:02 EST CareTrust REIT acquires Midwest skilled nursing portfolio for $97M - CareTrust REIT announced that it has acquired a 46-facility, 3,820-bed/unit skilled nursing and seniors housing portfolio located in the Midwest for a total investment amount of approximately $97M. Seven of the 46 facilities acquired are skilled nursing and assisted living campuses and an additional seven are assisted living facilities. In connection with the acquisition, the company entered into a triple-net master lease with a large skilled nursing investor and operator who will sublease the portfolio to several licensed subtenant operators. The new master lease has an initial term of 15 years with two, 5-year extension options and provides for a year 1 contractual lease yield of 11%. The master lease provides for some deferral of base rent in lease years 1 and 2 resulting in a cash rent yield of 9.0% in year 1 and 10.5% in year 2. Annual CPI-based rent escalators begin in year 4 and continue each remaining year of the lease term. The acquisition was completed in coordination with the bankruptcy and sale of all assets of the debtor/seller. The master tenant has been granted purchase options for each sub-portfolio, with most purchase options opening in lease years 4 and 5. With the exercise of each purchase option, additional rent payments to CareTrust may be triggered up to an aggregate, annual 12.5% yield on CareTrust's investment amount.

05:44 EST Samsara extends long-term collaboration with Fraikin Group - Fraikin Group is extending its long-standing collaboration with Samsara as part of its increased investment in digitalizing and decarbonizing its fleet. Fraikin is integrating Samsara's AI technologies across 60,000 vehicles throughout its European operations.

05:33 EST Innate Pharma announces new data from TELLOMAK study - Innate Pharma announced new data highlighting the quality-of-life improvements observed in patients with cutaneous T-cell lymphoma, or CTCL, treated with lacutamab in the TELLOMAK Phase 2 clinical study. These data were presented at the 66th American Society of Hematology, or ASH, annual meeting in San Diego, California. The TELLOMAK study addresses an unmet need for patients with advanced-stage CTCL, particularly Sezary syndrome and mycosis fungoides, who often experience debilitating symptoms such as severe itching and recurrent skin infections that profoundly impact their physical and social well-being. Patients with relapsed or refractory CTCL face limited treatment options and often report lower health-related quality of life, particularly those in advanced stages. TELLOMAK's findings reveal signs that lacutamab may help alleviate some of the most distressing symptoms of this disease early on treatment. The TELLOMAK trial enrolled 163 patients with advanced CTCL, including 56 with SS and 107 with MF. The study's quality of life measures included the Visual Analogue Scale, or VAS, for itch intensity and the Skindex-29 score, a validated tool for assessing the impact of skin conditions on patient quality of life.

05:26 EST PureTech Health presents data from dose escalation phase of LYT-200 trial - PureTech Health presented data from the dose escalation phase of its ongoing Phase 1b trial evaluating LYT-200, an anti-galectin-9 monoclonal antibody, in patients with relapsed or refractory acute myeloid leukemia, or AML, and myelodysplastic syndromes, or MDS, at the 2024 American Society of Hematology, or ASH, annual meeting in San Diego, California. LYT-200 is currently being evaluated both as a monotherapy and in combination with the venetoclax and hypomethylating agents, or HMA, for patients whose disease is relapsed/refractory to at least one line of prior treatment. It targets galectin-9, a glycan-binding protein that is significantly upregulated in AML and MDS and plays a role in disease development, progression, immune interference and drug resistance. Initial results show a favorable safety profile across both arms and all dose levels with no dose limiting toxicities, as well as evidence of response, hematological improvement and sustained disease management. In the monotherapy arm, patients received LYT-200 at five dose levels. Across all dose levels, LYT-200 induced clinical benefit and responses in heavily pre-treated, relapsed/refractory AML/MDS patients, even in those with complex cytogenetics and mutations such as KRAS, NRAS, BRAF as well as patients previously fully refractory to standard of care. Out of 22 evaluable patients who received monotherapy, 59% achieved stable disease or better with two partial responses. The mean duration on treatment is greater than two months, which exceeds the standard overall survival of approximately 1.7 months in venetoclax/HMA-refractory patients. When administered in combination with venetoclax/HMA, results demonstrate that LYT-200 may enhance the efficacy of standard-of-care therapies, even in relapsed or refractory patients. In the combination arm, patients received LYT-200 across three dose levels with venetoclax/HMA. Out of 15 evaluable patients who received combination therapy, 80% achieved stable disease or better, with two experiencing complete responses and one patient achieving a morphologic leukemia free state. The combination regimen has also demonstrated clinical benefit in patients with KRAS/NRAS mutations and the mean duration on treatment up until the point of data cut-off is greater than two months. Pharmacodynamic assessments of treated patients, using gene and protein analyses of patient cells, validate the LYT-200 dual mode of action, and reveal AML cellular pathways as well as specific immune cell types which may be most critical for response. Based on these data, LYT-200 will continue development in relapsed/refractory AML/MDS towards a Phase 2 clinical trial. PureTech previously announced that it intends to advance LYT-200 via its Founded Entity, Gallop Oncology.

05:20 EST MaxCyte to reduce workforce by 15% following internal review - MaxCyte announced the completion of an internal operational review, initiated earlier this year following the appointment of Maher Masoud as president and CEO. This "bottom-up" review focused on optimizing new product development, manufacturing, commercial execution, and capital allocation to enhance efficiency and align resources with strategic priorities. As part of an effort to streamline operations, the company made adjustments to its workforce which affected 21 positions, reflecting approximately 15% of its personnel globally, including both directly employed individuals and those engaged through third-party employer-of-record arrangements. Anticipated cost savings in 2025 as a result of this action are expected to be about $5.8M. Following this adjustment, combined with other personnel decisions made throughout the year, MaxCyte expects to end the year with 116 employees, compared with 143 employees at the end of 2023.

05:04 EST Apollo. Banco Santander partner on $370M infrastructure portfolio financing - Apollo (APO) and Santander (SAN) announced that Apollo-managed funds and affiliates have agreed to invest in an approximately $370M portfolio of infrastructure credit. The transaction was led by Apterra, an affiliate of Apollo founded in 2023 that specializes in financing solutions for infrastructure projects.